<?xml version="1.0" encoding="ISO-8859-1"?><COCHRANE_REVIEW DESCRIPTION="For publication" DOI="10.1002/14651858.CD006606.pub2" GROUP_ID="MENSTR" ID="006906120502380331" MERGED_FROM="" MODIFIED="2013-09-22 16:03:59 +0100" MODIFIED_BY="Helen Nagels" REVIEW_NO="CS1400" REVMAN_SUB_VERSION="5.2.6 " REVMAN_VERSION="5" SPLIT_FROM="" STAGE="R" STATUS="A" TYPE="INTERVENTION" VERSION_NO="5.0">
<COVER_SHEET MODIFIED="2013-09-22 16:03:59 +0100" MODIFIED_BY="Helen Nagels">
<TITLE MODIFIED="2011-03-09 15:52:57 +1300" MODIFIED_BY="[Empty name]">In vitro maturation in subfertile women with polycystic ovarian syndrome undergoing assisted reproduction</TITLE>
<CONTACT MODIFIED="2013-09-22 16:03:59 +0100" MODIFIED_BY="Helen Nagels"><PERSON ID="BA4240AF82E26AA201074938D59DD6B8" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Charalampos</FIRST_NAME><MIDDLE_INITIALS>S</MIDDLE_INITIALS><LAST_NAME>Siristatidis</LAST_NAME><POSITION>Assistant Professor of Medicine</POSITION><EMAIL_1>harrysiri@yahoo.gr</EMAIL_1><EMAIL_2>harrysiris@gmail.com</EMAIL_2><MOBILE_PHONE>0030 6932 294994</MOBILE_PHONE><ADDRESS><DEPARTMENT>Assisted Reproduction Unit, 3rd Department of Obstetrics and Gynaecology</DEPARTMENT><ORGANISATION>University of Athens</ORGANISATION><ADDRESS_1>Attikon University Hospital,</ADDRESS_1><ADDRESS_2>Rimini 1</ADDRESS_2><CITY>Athens</CITY><ZIP>12462</ZIP><REGION>Chaidari</REGION><COUNTRY CODE="GR">Greece</COUNTRY><PHONE_1>0030 210 5832283</PHONE_1></ADDRESS></PERSON></CONTACT>
<CREATORS MODIFIED="2013-09-22 16:03:59 +0100" MODIFIED_BY="Helen Nagels"><PERSON ID="BA4240AF82E26AA201074938D59DD6B8" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Charalampos</FIRST_NAME><MIDDLE_INITIALS>S</MIDDLE_INITIALS><LAST_NAME>Siristatidis</LAST_NAME><POSITION>Assistant Professor of Medicine</POSITION><EMAIL_1>harrysiri@yahoo.gr</EMAIL_1><EMAIL_2>harrysiris@gmail.com</EMAIL_2><MOBILE_PHONE>0030 6932 294994</MOBILE_PHONE><ADDRESS><DEPARTMENT>Assisted Reproduction Unit, 3rd Department of Obstetrics and Gynaecology</DEPARTMENT><ORGANISATION>University of Athens</ORGANISATION><ADDRESS_1>Attikon University Hospital,</ADDRESS_1><ADDRESS_2>Rimini 1</ADDRESS_2><CITY>Athens</CITY><ZIP>12462</ZIP><REGION>Chaidari</REGION><COUNTRY CODE="GR">Greece</COUNTRY><PHONE_1>0030 210 5832283</PHONE_1></ADDRESS></PERSON><PERSON ID="z1305280657528049057262778990218" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Nikos</FIRST_NAME><LAST_NAME>Vrachnis</LAST_NAME><POSITION>Assistant Professor of Obstetrics and Gynecology</POSITION><EMAIL_1>nvrachnis@hotmail.com</EMAIL_1><ADDRESS><DEPARTMENT>2nd Department of Obstetrics and Gynecology - Aretaieio Hospital</DEPARTMENT><ORGANISATION>University of Athens - Medical School</ORGANISATION><ADDRESS_1>76 Vas. Sophias</ADDRESS_1><CITY>Athens</CITY><ZIP>115 26</ZIP><COUNTRY CODE="GR">Greece</COUNTRY></ADDRESS></PERSON><PERSON ID="z1305280654137588252234805478803" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Maria</FIRST_NAME><LAST_NAME>Creatsa</LAST_NAME><POSITION>Clinical and Research Fellow</POSITION><EMAIL_1>mar_kreatsa@yahoo.gr</EMAIL_1><ADDRESS><DEPARTMENT>Assisted Reproduction Unit, 3rd Department of Obstetrics and Gynaecology</DEPARTMENT><ORGANISATION>University of Athens</ORGANISATION><CITY>Athens</CITY><COUNTRY CODE="GR">Greece</COUNTRY></ADDRESS></PERSON><PERSON ID="54682FAE82E26AA201BA4B547E28EB68" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Abha</FIRST_NAME><LAST_NAME>Maheshwari</LAST_NAME><POSITION>Senior Lecturer and Consultant in Reproductive Medicine</POSITION><EMAIL_1>abha.maheshwari@abdn.ac.uk</EMAIL_1><ADDRESS><DEPARTMENT>Division of Applied Health Sciences</DEPARTMENT><ORGANISATION>University of Aberdeen</ORGANISATION><CITY>Aberdeen</CITY><ZIP>AB25 2ZL</ZIP><COUNTRY CODE="GB">UK</COUNTRY><PHONE_1>01224-554976</PHONE_1></ADDRESS></PERSON><PERSON ID="18315" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Siladitya</FIRST_NAME><LAST_NAME>Bhattacharya</LAST_NAME><EMAIL_1>s.bhattacharya@abdn.ac.uk</EMAIL_1><ADDRESS><DEPARTMENT>Obstetrics and Gynaecology</DEPARTMENT><ORGANISATION>Aberdeen Maternity Hospital</ORGANISATION><ADDRESS_2>Foresterhill</ADDRESS_2><CITY>Aberdeen</CITY><ZIP>AB9 2ZD</ZIP><COUNTRY CODE="GB">UK</COUNTRY><PHONE_1>+44 1224 681 818</PHONE_1><FAX_1>+44 1224 684 880</FAX_1></ADDRESS></PERSON></CREATORS>
<DATES MODIFIED="2013-07-19 14:43:31 +1200" MODIFIED_BY="[Empty name]">
<UP_TO_DATE>
<DATE DAY="1" MONTH="5" YEAR="2013"/>
</UP_TO_DATE>
<LAST_SEARCH>
<DATE DAY="1" MONTH="5" YEAR="2013"/>
</LAST_SEARCH>
<NEXT_STAGE>
<DATE DAY="1" MONTH="5" YEAR="2015"/>
</NEXT_STAGE>
<PROTOCOL_PUBLISHED ISSUE="3" YEAR="2007"/>
<REVIEW_PUBLISHED ISSUE="1" YEAR="2009"/>
<LAST_CITATION_ISSUE ISSUE="1" YEAR="2009"/>
</DATES>
<WHATS_NEW MODIFIED="2013-08-19 16:12:24 +1200" MODIFIED_BY="[Empty name]">
<WHATS_NEW_ENTRY EVENT="NEW_CITATION_OLD_CONCLUSIONS" MODIFIED="2013-08-19 16:12:24 +1200" MODIFIED_BY="[Empty name]">
<DATE DAY="23" MONTH="7" YEAR="2013"/>
<DESCRIPTION>
<P>Update of methods; still no studies available for inclusion.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="UPDATE" MODIFIED="2013-08-05 07:40:38 +1200" MODIFIED_BY="[Empty name]">
<DATE DAY="23" MONTH="7" YEAR="2013"/>
<DESCRIPTION>
<P>Update of studies and methods, one study reported as RCT was excluded, three ongoing studies were found reporting no results, final conclusion not changed.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</WHATS_NEW>
<HISTORY MODIFIED="2013-07-08 15:17:42 +1200" MODIFIED_BY="[Empty name]">
<WHATS_NEW_ENTRY EVENT="UPDATE" MODIFIED="2013-07-08 15:17:42 +1200" MODIFIED_BY="[Empty name]">
<DATE DAY="7" MONTH="4" YEAR="2011"/>
<DESCRIPTION>
<P>To be made stable </P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="NEW_CITATION_MAJOR">
<DATE DAY="22" MONTH="1" YEAR="2008"/>
<DESCRIPTION>
<P>Substantive amendment</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</HISTORY>
<SOURCES_OF_SUPPORT MODIFIED="2008-09-20 00:19:30 +1200" MODIFIED_BY="[Empty name]">
<INTERNAL_SOURCES MODIFIED="2008-09-20 00:19:30 +1200" MODIFIED_BY="[Empty name]">
<SOURCE MODIFIED="2008-09-20 00:19:30 +1200" MODIFIED_BY="[Empty name]">
<NAME>University of Aberdeen</NAME>
<COUNTRY CODE="GB">UK</COUNTRY>
<DESCRIPTION>
<P>Assisted Reproduction Unit, University of Aberdeen UK.</P>
</DESCRIPTION>
</SOURCE>
</INTERNAL_SOURCES>
<EXTERNAL_SOURCES/>
</SOURCES_OF_SUPPORT>
<MESH_TERMS VERIFIED="NO"/>
<KEYWORDS/>
</COVER_SHEET>
<MAIN_TEXT MODIFIED="2013-08-20 10:57:57 +1200" MODIFIED_BY="[Empty name]">
<SUMMARY MODIFIED="2013-08-06 03:10:25 +1200" MODIFIED_BY="[Empty name]">
<TITLE MODIFIED="2013-07-18 13:31:01 +1200" MODIFIED_BY="[Empty name]">In vitro maturation in subfertile women with polycystic ovarian  hyperstimulation syndrome who are undergoing assisted reproduction</TITLE>
<SUMMARY_BODY MODIFIED="2013-08-06 03:10:25 +1200" MODIFIED_BY="[Empty name]">
<P>
<B>Background</B>
<BR/>Women with polycystic ovarian syndrome undergoing conventional assisted reproduction techniques are at an increased risk of ovarian hyperstimulation. Since polycystic ovarian syndrome is often associated with the retrieval of immature oocytes, poor fertilisation, and low pregnancy rates, women with polycystic ovarian syndrome undergoing conventional assisted reproduction techniques are at an increased risk of ovarian hyperstimulation. Thus, these women might benefit from the earlier retrieval of oocytes followed by maturation of the oocytes in the laboratory (in vitro maturation - IVM) as this would reduce the aforementioned risks. However, while successful fertilisation, embryo development, and term pregnancies resulting from IVM oocytes have been reported, along with some concern has been expressed regarding the safety of the method with respect to the health of the children and the rate of congenital anomalies. We reviewed the evidence up to May 2013.</P>
<P>
<B>Findings</B>
<BR/>We found no randomised controlled trials with results to help assess the risks and benefits of IVM in infertile women with polycystic ovarian syndrome as compared to conventional assisted reproduction technology techniques. We are unable to make any recommendations but note that there are three ongoing trials whose results are awaited.</P>
</SUMMARY_BODY>
</SUMMARY>
<ABSTRACT MODIFIED="2013-08-19 16:12:40 +1200" MODIFIED_BY="[Empty name]">
<ABS_BACKGROUND MODIFIED="2013-08-06 02:52:34 +1200" MODIFIED_BY="[Empty name]">
<P>Polycystic ovarian syndrome (PCOS) occurs in 4% to 7% of all women of reproductive age and 50% of women presenting with subfertility. Subfertility affects 15% to 20% of couples trying to conceive. A significant proportion of these women ultimately need assisted reproductive technology (ART). In vitro fertilisation (IVF) is one of the assisted reproduction techniques employed to raise the chances of achieving a pregnancy. For the standard IVF technique, stimulating follicle development and growth before oocyte retrieval is essential, for which a large number of different methods combining gonadotrophins with a gonadotrophin-releasing hormone (GnRH) agonist or antagonist are used. In women with PCOS, the supra-physiological doses of gonadotrophins used for controlled ovarian hyperstimulation (COH) often result in an exaggerated ovarian response, characterised by the development of a large cohort of follicles of uneven quality, retrieval of immature oocytes, and increased risk of ovarian hyperstimulation syndrome. A potentially effective intervention for women with PCOS-related subfertility involves earlier retrieval of immature oocytes at the germinal-vesicle stage followed by in vitro maturation (IVM). So far, the only data available have derived from observational studies and non-randomised clinical trials.</P>
</ABS_BACKGROUND>
<ABS_OBJECTIVES MODIFIED="2013-08-19 16:12:40 +1200" MODIFIED_BY="[Empty name]">
<P>To compare outcomes associated with in vitro maturation (IVM) followed by vitro fertilisation (IVF) or intracytoplasmic sperm injection (ICSI) versus conventional IVF or ICSI, among women with polycystic ovarian syndrome (PCOS) undergoing assisted reproductive technologies (ART).</P>
</ABS_OBJECTIVES>
<ABS_SEARCH_STRATEGY MODIFIED="2013-08-06 02:52:41 +1200" MODIFIED_BY="[Empty name]">
<P>We searched the Menstrual Disorders and Subfertility Group (MDSG) Specialised Register of controlled trials to May 2013 for any relevant trials identified from the title, abstract, or keyword sections. This was followed by a search of the electronic database MEDLINE, EMBASE, LILACS and CINAHL, without language restriction. We also performed a manual search of the references of all retrieved articles; sought unpublished papers and abstracts submitted to international conferences, searched the clinicaltrials.gov and WHO portal registries for submitted protocols of clinical trials, and contacted experts. In addition, we examined the National Institute of Clinical Excellence (NICE) fertility assessment and treatment guidelines and handsearched reference lists of relevant articles (from 1970 to May 2013).</P>
</ABS_SEARCH_STRATEGY>
<ABS_SELECTION_CRITERIA MODIFIED="2013-08-06 02:52:45 +1200" MODIFIED_BY="[Empty name]">
<P>All randomised trials (RCTs) on the intention to perform IVM before IVF or ICSI compared with conventional IVF or ICSI for subfertile women with PCOS.</P>
</ABS_SELECTION_CRITERIA>
<ABS_DATA_COLLECTION MODIFIED="2013-06-09 04:48:55 +1200" MODIFIED_BY="[Empty name]">
<P>Three review authors (CS, MK and NV) independently assessed eligibility and quality of trials. Primary outcome measure was live birth rate per randomised woman.</P>
</ABS_DATA_COLLECTION>
<ABS_RESULTS MODIFIED="2013-06-11 09:21:17 +1200" MODIFIED_BY="jane clarke">
<P>There were no RCTs suitable for inclusion in the review, although there are currently three ongoing trials that have not yet reported results.</P>
</ABS_RESULTS>
<ABS_CONCLUSIONS MODIFIED="2013-07-18 13:05:42 +1200" MODIFIED_BY="[Empty name]">
<P>Though promising data on the IVM technique have been published, unfortunately there is still no evidence from RCTs upon which to base any practice recommendations regarding IVM before IVF or ICSI for women with PCOS. Meanwhile, the results of the above-mentioned ongoing trials are awaited and, of course, further evidence from good quality trials in the field is eagerly anticipated.</P>
</ABS_CONCLUSIONS>
</ABSTRACT>
<BODY MODIFIED="2013-08-20 10:57:57 +1200" MODIFIED_BY="[Empty name]">
<BACKGROUND MODIFIED="2013-08-19 16:50:08 +1200" MODIFIED_BY="[Empty name]">
<P>
<BR/>
</P>
<CONDITION MODIFIED="2013-08-19 16:50:08 +1200" MODIFIED_BY="[Empty name]">
<P>Polycystic ovarian syndrome (PCOS) occurs in 4% to 7% of all women of reproductive age (<LINK REF="REF-Archer-2004" TYPE="REFERENCE">Archer 2004</LINK>) and 50% of women who will seek subfertility services at some point in their life (<LINK REF="REF-Azziz-2005" TYPE="REFERENCE">Azziz 2005</LINK>). Clear diagnostic criteria for this condition were drawn up at a consensus meeting of the European Society of Human Reproduction and Embryology (ESHRE) and the American Society for Reproductive Medicine (ASRM) (<LINK REF="REF-ESHRE_x002f_ASRM-2003" TYPE="REFERENCE">ESHRE/ASRM 2003</LINK>), while more recently it has been proposed that definitions be based on AMH levels of &gt; 5 ng/mL (<LINK REF="REF-Dewailly-2011" TYPE="REFERENCE">Dewailly 2011</LINK>). In anovulatory women with PCOS, lifestyle changes (weight loss and exercise) along with clomiphene citrate remain the first-line approach to subfertility. Other recognised options include surgical ovarian wedge resection, laparoscopic ovarian drilling, metformin, bromocryptine, or aromatase inhibitors (<LINK REF="REF-NICE-2004" TYPE="REFERENCE">NICE 2004</LINK>).<BR/>
<BR/>A proportion of women with PCOS do not respond to these conventional treatments and will ultimately need assisted reproductive techniques (ART). In women with PCOS, supra-physiological doses of gonadotrophins that are used for controlled ovarian hyperstimulation (COH) provoke the development of a large cohort of follicles of uneven quality. This can sometimes result in the retrieval of immature oocytes, which leads to poor fertilisation and lower cleavage, pregnancy, and live birth rates. Proposed addition of melatonin into the in vitro maturation (IVM) media has been suggested to improve the cytoplasmic maturation of the immature oocytes and the subsequent clinical outcomes (Kim 2013). Controlled ovarian hyperstimulation in women with PCOS poses a particular challenge as many of these women exhibit an exaggerated response to exogenous gonadotrophins (<LINK REF="REF-MacDougall-1993" TYPE="REFERENCE">MacDougall 1993</LINK>), although there is evidence that COH in women with PCOS results in similar outcomes when compared to women without PCOS (<LINK REF="REF-Heijnen-2006" TYPE="REFERENCE">Heijnen 2006</LINK>). As a consequence, many face an increased rate of cycle cancellations and potential life-threatening complications due to ovarian hyperstimulation syndrome (OHSS).</P>
</CONDITION>
<INTERVENTION MODIFIED="2013-08-19 16:43:39 +1200" MODIFIED_BY="[Empty name]">
<P>In vitro maturation involves the retrieval of immature oocytes (at the germinal vesicle stage) followed by growth in culture up to the metaphase II stage. This can be a potentially useful intervention for women with PCOS-related subfertility since these oocytes can retain their maturational and developmental competence (<LINK REF="STD-Trounson-1994" TYPE="STUDY">Trounson 1994</LINK>). It is believed that women with PCOS who are at risk of developing OHSS following a conventional COH regimen, might benefit from earlier retrieval of oocytes followed by IVM, thus reducing the risk of OHSS. In addition, doses and cost of the drugs would be lower. On the other hand, the process of IVM could affect the quality of oocytes as any intervention in their growth phase could affect oocyte maturation, fertilisation, and subsequent embryo development (<LINK REF="REF-Trounson-2001" TYPE="REFERENCE">Trounson 2001</LINK>), leading to poor pregnancy outcomes (<LINK REF="STD-Barnes-1996" TYPE="STUDY">Barnes 1996</LINK>; <LINK REF="REF-Suikkari-2008" TYPE="REFERENCE">Suikkari 2008</LINK>; <LINK REF="REF-Son-2010" TYPE="REFERENCE">Son 2010</LINK>; <LINK REF="REF-Qiao-2011" TYPE="REFERENCE">Qiao 2011</LINK>; <LINK REF="REF-Cakmak-2011" TYPE="REFERENCE">Cakmak 2011</LINK>; <LINK REF="REF-Qiao-2011" TYPE="REFERENCE">Qiao 2011</LINK>; Zheng 2012; <LINK REF="REF-de-Ziegler-2012" TYPE="REFERENCE">de Ziegler 2012</LINK>).</P>
</INTERVENTION>
<THEORY MODIFIED="2013-07-18 13:35:53 +1200" MODIFIED_BY="[Empty name]">
<P>An option for subfertile women with PCOS is the retrieval of oocytes that retain their functional competence with minimal or mild gonadotrophin stimulation, which stimulates the endometrium at a very low or zero level, mimicking natural environmental procedures. Successful fertilisation, embryo development, and term pregnancy resulting from IVM oocytes have been reported in stimulated cycles (<LINK REF="REF-Nagy-1996" TYPE="REFERENCE">Nagy 1996</LINK>; <LINK REF="STD-Child-2001" TYPE="STUDY">Child 2001</LINK>), natural cycles (<LINK REF="STD-Mikkelsen-2001" TYPE="STUDY">Mikkelsen 2001</LINK>; <LINK REF="REF-Yoon-2001" TYPE="REFERENCE">Yoon 2001</LINK>; <LINK REF="REF-Fadini-2009" TYPE="REFERENCE">Fadini 2009</LINK>; <LINK REF="STD-Benkhalifa-2009" TYPE="STUDY">Benkhalifa 2009</LINK>; <LINK REF="REF-Fadini-2013" TYPE="REFERENCE">Fadini 2013</LINK>), and women with PCOS (<LINK REF="STD-Trounson-1994" TYPE="STUDY">Trounson 1994</LINK>; <LINK REF="STD-Beckers-1999" TYPE="STUDY">Beckers 1999</LINK>; <LINK REF="STD-Chian-1999" TYPE="STUDY">Chian 1999</LINK>; <LINK REF="STD-Cha-2000" TYPE="STUDY">Cha 2000</LINK>; <LINK REF="STD-Chian-2000" TYPE="STUDY">Chian 2000</LINK>; <LINK REF="STD-Child-2001" TYPE="STUDY">Child 2001</LINK>; <LINK REF="STD-Child-2002" TYPE="STUDY">Child 2002</LINK>; <LINK REF="STD-Lin-2003" TYPE="STUDY">Lin 2003</LINK>; <LINK REF="REF-Liu-2003" TYPE="REFERENCE">Liu 2003</LINK>; <LINK REF="STD-Gulekli-2004" TYPE="STUDY">Gulekli 2004</LINK>; <LINK REF="STD-Le-Du-2005" TYPE="STUDY">Le Du 2005</LINK>; <LINK REF="STD-Soderstrom_x002d_Anttila-2005" TYPE="STUDY">Soderstrom-Anttila 2005</LINK>; <LINK REF="STD-Son-2005" TYPE="STUDY">Son 2005</LINK>; <LINK REF="STD-Zhao-2006" TYPE="STUDY">Zhao 2006</LINK>; <LINK REF="STD-Son-2007" TYPE="STUDY">Son 2007</LINK>; <LINK REF="STD-Zhao-2009" TYPE="STUDY">Zhao 2009</LINK>; <LINK REF="STD-Roesner-2012" TYPE="STUDY">Roesner 2012</LINK>), with the first report having been published in<I> </I>the mid 1960s (<LINK REF="REF-Edwards-1965" TYPE="REFERENCE">Edwards 1965</LINK>). While some concern has been expressed regarding the safety of the method with respect to the health of the children and the rate of congenital anomalies (<LINK REF="STD-Cha-2005" TYPE="STUDY">Cha 2005</LINK>), other studies have reported normal obstetric and neonatal outcomes (<LINK REF="STD-Soderstrom_x002d_Anttila-2005" TYPE="STUDY">Soderstrom-Anttila 2005</LINK>; <LINK REF="REF-Mikkelsen-2005" TYPE="REFERENCE">Mikkelsen 2005</LINK>; <LINK REF="STD-Shu_x002d_Shi-2006" TYPE="STUDY">Shu-Shi 2006</LINK>; <LINK REF="STD-Buckett-2007" TYPE="STUDY">Buckett 2007</LINK>; <LINK REF="STD-Buckett-2008" TYPE="STUDY">Buckett 2008</LINK>).</P>
</THEORY>
<IMPORTANCE MODIFIED="2013-07-18 13:10:21 +1200" MODIFIED_BY="[Empty name]">
<P>When choosing between different IVF protocols for subfertile women with PCOS a balance needs to be achieved between benefits and harms. Successful fertilisation, embryo development and term pregnancy resulting from IVM oocytes have been reported in stimulated cycles. However, despite the publication of a number of studies in this area that have shown that IVM is a low-risk and patient-friendly procedure, it is unclear whether IVM offers any benefit to women with PCOS who are undergoing COH, as an alternative to conventional IVF. We have therefore undertaken an update of a systematic review of the literature to ascertain whether IVM is superior to conventional IVF treatment in women with PCOS.</P>
</IMPORTANCE>
</BACKGROUND>
<OBJECTIVES MODIFIED="2013-08-05 21:02:44 +1200" MODIFIED_BY="[Empty name]">
<P>To compare outcomes associated with in vitro maturation (IVM) followed by vitro fertilisation (IVF) or intracytoplasmic sperm injection (ICSI) versus conventional IVF or ICSI, among women with polycystic ovarian syndrome (PCOS) undergoing assisted reproductive technologies (ART).</P>
</OBJECTIVES>
<METHODS MODIFIED="2013-08-19 16:12:58 +1200" MODIFIED_BY="[Empty name]">
<SELECTION_CRITERIA MODIFIED="2013-08-06 02:56:11 +1200" MODIFIED_BY="[Empty name]">
<CRIT_STUDIES MODIFIED="2013-08-06 02:53:54 +1200" MODIFIED_BY="[Empty name]">
<P>Randomised controlled trials (RCTs) that compared IVM with conventional ART (IVF or ICSI) in women with PCOS were considered for inclusion in this review. If a factorial design was identified (for example, trials with four groups: IVM alone, IVF alone, IVM + drug, IVF + drug) data would be pooled where IVM followed by IVF or ICSI was compared with conventional IVF or ICSI.<BR/>
<BR/>Quasi-randomised trials were not included. Cross-over trials were not eligible for inclusion unless pre-cross-over data were available, in which case only these data would be used for the purposes of the review.</P>
</CRIT_STUDIES>
<CRIT_PARTICIPANTS MODIFIED="2013-08-06 02:55:57 +1200" MODIFIED_BY="[Empty name]">
<SUBSECTION>
<HEADING LEVEL="4">Inclusion criteria</HEADING>
<P>All studies that included subfertile women described as having PCOS were eligible. PCOS was defined by the ESHRE/ASRM criteria (<LINK REF="REF-ESHRE_x002f_ASRM-2003" TYPE="REFERENCE">ESHRE/ASRM 2003</LINK>). In consideration of the wide variation of diagnostic criteria used for PCOS studies, studies utilising different criteria were included if the broad definition matched that of the ESHRE/ASRM criteria.</P>
<P>Trials including couples with various categories of subfertility alongside PCOS, irrespective of age, parity and previously administered treatments for subfertility were also included. If only pooled data were available, a study was eligible if at least 80% of participants had PCOS.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Exclusion criteria</HEADING>
<P>Trials of ovum recipients and others in which assisted hatching was used were excluded, as an issue of embryo quality impairment might be introduced. Had there been insufficient information about the clinical diagnosis, we would have contacted the authors of primary trials.</P>
</SUBSECTION>
</CRIT_PARTICIPANTS>
<CRIT_INTERVENTIONS MODIFIED="2013-08-06 02:56:11 +1200" MODIFIED_BY="[Empty name]">
<P>Conventional IVF or ICSI after controlled ovarian hyperstimulation (COH) versus IVM followed by IVF or ICSI. Embryo transfers of both fresh and frozen, but not mixed embryos were included.<BR/>
<BR/>Trials evaluating alternative interventions in which the option of IVM or conventional ART was not randomised (for example ovarian drilling, use of the oral contraceptive pill, metformin, aromatase inhibitors, steroids, progestins, growth hormone, L-arginine) were excluded.</P>
<P>Studies using different protocols for IVM, for example human chorionic gonadotrophin (HCG) or gonadotrophin priming for the maturation of oocytes before IVM, were eligible as long as they compared women with PCOS undergoing COH programmes.</P>
<P>All ovarian stimulation protocols were eligible (use of gonadotrophin-releasing hormone agonists (GnRHa), GnRH antagonists, gonadotrophins alone (recombinant or urinary preparations), or clomiphene with gonadotrophins). In all the above cases, pooling data was our intended purpose.</P>
</CRIT_INTERVENTIONS>
<CRIT_OUTCOMES MODIFIED="2013-08-05 21:20:38 +1200" MODIFIED_BY="[Empty name]">
<CRIT_OUTCOMES_PRIMARY MODIFIED="2013-08-05 21:20:38 +1200" MODIFIED_BY="[Empty name]">
<P>1. Live birth per woman. Defined as the delivery of one or more living fetuses after 20 completed weeks of gestation. No cumulative results from more than one cycle were to be considered</P>
</CRIT_OUTCOMES_PRIMARY>
<CRIT_OUTCOMES_SECONDARY MODIFIED="2013-07-08 16:56:01 +1200" MODIFIED_BY="[Empty name]">
<P>1. Effectiveness</P>
<UL>
<LI>Clinical pregnancy per woman, where clinical pregnancy was defined as evidence of a fetal heart on ultrasound at seven plus two gestational weeks</LI>
<LI>Cycle cancellation rate</LI>
<LI>Oocyte fertilisation rate</LI>
<LI>Ovarian hyperstimulation</LI>
</UL>
<P>2. Adverse effects</P>
<UL>
<LI>Miscarriage rate</LI>
<LI>Preterm birth</LI>
<LI>Congenital anomalies of the newborn</LI>
</UL>
</CRIT_OUTCOMES_SECONDARY>
</CRIT_OUTCOMES>
</SELECTION_CRITERIA>
<SEARCH_METHODS MODIFIED="2013-08-06 02:57:24 +1200" MODIFIED_BY="[Empty name]">
<P>We searched for all published and unpublished randomised controlled trials, studying IVM versus IVF/ICSI in subfertile women with POCS. We applied no language restrictions. The search was designed with the help of the Menstrual Disorders and Subfertility Group Trials Search Co-ordinator.</P>
<ELECTRONIC_SEARCHES MODIFIED="2013-08-06 02:57:24 +1200" MODIFIED_BY="[Empty name]">
<P>
<BR/>(1) The Menstrual Disorders and Subfertility Group Specialised Register of controlled trials was searched for any relevant trials from the title, abstract, or keyword sections</P>
<P>(2) The following electronic databases were also searched:</P>
<P>MEDLINE and PubMed (http://www.ncbi.nlm.nih.gov/pubmed/) (1966 to May 2013) (<LINK REF="APP-01" TYPE="APPENDIX">Appendix 1</LINK>), CENTRAL (the Menstrual Disorders and Subfertility Group&#8217;s Central register of Controlled Trials) (1966 to May 2013) (<LINK REF="APP-02" TYPE="APPENDIX">Appendix 2</LINK>), CINHAL (1966 to May 2013) (<LINK REF="APP-03" TYPE="APPENDIX">Appendix 3</LINK>), EMBASE (1966 to May 2013) (<LINK REF="APP-04" TYPE="APPENDIX">Appendix 4</LINK>) and the Trial registers for ongoing and registered trials: 'ClinicalTrials.gov', a service of the US National Institutes of Health (http://clinicaltrials.gov/ct2/home) and The World Health Organization International Trials Registry Platform search portal (http://www.who.int/trialsearch/Default.aspx) (<LINK REF="APP-05" TYPE="APPENDIX">Appendix 5</LINK>) and OpenSIGLE database for grey literature from Europe (http://opensigle.inist.fr/).<BR/>
</P>
</ELECTRONIC_SEARCHES>
<OTHER_SEARCHES MODIFIED="2013-07-18 13:44:10 +1200" MODIFIED_BY="[Empty name]">
<P>Further searches were made in the National Institute of Clinical Excellence (NICE) fertility assessment and treatment guidelines (<LINK REF="REF-NICE-2004" TYPE="REFERENCE">NICE 2004</LINK>). Reference lists of relevant systematic reviews and RCTs were handsearched.</P>
</OTHER_SEARCHES>
</SEARCH_METHODS>
<DATA_COLLECTION MODIFIED="2013-08-19 16:12:58 +1200" MODIFIED_BY="[Empty name]">
<STUDY_SELECTION MODIFIED="2013-08-05 21:20:21 +1200" MODIFIED_BY="[Empty name]">
<P>Three review authors (CS, MK and NV) independently checked the titles and abstracts retrieved by the search and examined them for compliance with the above criteria. It was our intention that additional information would be sought from the authors of trials which appeared to meet the eligibility criteria but had either aspects of methodology that were unclear or data in an unsuitable form for meta-analysis. Differences of opinion were to be resolved after correspondence with AM and SB.</P>
</STUDY_SELECTION>
<DATA_EXTRACTION MODIFIED="2013-08-19 16:12:58 +1200" MODIFIED_BY="[Empty name]">
<P>Our intention was to extract the following data from the studies included in the review.</P>
<SUBSECTION>
<HEADING LEVEL="6">
<I>1. </I>Trial characteristics</HEADING>
<P>(a) Randomisation (truly randomised, pseudo-randomised, or not stated)<BR/>(b) Allocation concealment, scored according to the categories used by The Cochrane Collaboration: (A) allocation concealment was adequate, (B) unclear, (C) inadequate, (D) allocation concealment was not used<BR/>(c) Trial design: multicentre or single-centre, single phase or cross-over design<BR/>(d) Duration, timing, and location of the trial (single-centre or multicentre), duration of follow-up: (A) outcome data used for primary analysis complete (follow-up to live birth), randomised women accounted for, intention-to-treat analysis; (B) completeness of data uncertain; (C) outcome data incomplete with 5% of cycles commenced missing some outcome data<BR/>(e) Source of funding<BR/>(f) Co-intervention: (A) where any intervention other than that being investigated in the study protocol was equivalent in the treatment and control groups; (B) issue of co-intervention not considered; (C) co-intervention definitely existed<BR/>(g) Definitions of PCOS were examined, e.g. If they matched the ASRM/ESHRE criteria, if they were too restrictive, or too vague</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="6">2. Baseline characteristics of the studied groups</HEADING>
<P>(a) Cause and duration of pre-existing subfertility<BR/>(b) Age of the women and parity<BR/>(c) Investigative work up<BR/>(d) Other causes of subfertility<BR/>(e) Previously administered treatment(s)<BR/>
</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="6">3. Interventions</HEADING>
<P>(a) Type of intervention and control<BR/>(b) Dose and type of regimen<BR/>
</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="6">4. Outcomes</HEADING>
<P>(a) Outcomes reported<BR/>(b) How outcomes were defined<BR/>(c) Timing of outcome measurements</P>
</SUBSECTION>
</DATA_EXTRACTION>
<QUALITY_ASSESSMENT MODIFIED="2013-08-06 02:58:35 +1200" MODIFIED_BY="[Empty name]">
<P>It was our intention that data on trial quality would be extracted in duplicate. This information would have been presented in the 'Characteristics of included studies' table to provide a context for discussing the reliability of results.</P>
</QUALITY_ASSESSMENT>
<EFFECT_MEASURES MODIFIED="2013-08-06 02:58:45 +1200" MODIFIED_BY="[Empty name]">
<P>For dichotomous data (e.g. live birth rates), our aim was to use the numbers of events in the control and intervention groups of each study to calculate Mantel-Haenszel odds ratios (ORs) with 95% confidence intervals (CIs) for all outcomes. Where data to calculate ORs were not available, we would have utilised the most detailed numerical data available that might facilitate similar analyses of included studies.<BR/>
</P>
</EFFECT_MEASURES>
<UNIT_OF_ANALYSIS MODIFIED="2013-08-06 02:59:04 +1200" MODIFIED_BY="[Empty name]">
<P>Our intention was that the primary analysis would be per woman randomised; per pregnancy data might also be included for some outcomes (e.g. miscarriage). Data that would not allow valid analysis (e.g. "per cycle" data) would be briefly summarised in an additional table but would not be meta-analysed. Multiple live births (e.g. twins or triplets) were to be counted as one live birth event. Only first-phase data from cross-over trials were to be included. If studies reported only &#8220;per cycle&#8221; data, we would have contacted authors to request &#8220;per woman&#8221; data.</P>
</UNIT_OF_ANALYSIS>
<MISSING_DATA MODIFIED="2013-08-06 02:59:56 +1200" MODIFIED_BY="[Empty name]">
<P>Attempts were made to obtain missing data from the original trialists of the three ongoing studies by sending the corresponding authors two e-mails. No data were obtained.</P>
<P>Our initial intention was to analyse the data on an intention-to-treat basis. Where these were unobtainable, imputation of individual values would have been undertaken for the primary outcomes only. Live births would be assumed not to have occurred in participants without a reported outcome. For other outcomes, only the available data would have been analysed. Any imputation undertaken would have been subjected to sensitivity analysis (see below).<BR/>
</P>
</MISSING_DATA>
<HETEROGENEITY_ASSESSMENT MODIFIED="2013-07-18 13:18:41 +1200" MODIFIED_BY="[Empty name]">
<P>It was our intention to consider whether the clinical and methodological characteristics of the included studies were sufficiently similar for meta-analysis to provide a clinically meaningful summary. We would have assessed statistical heterogeneity by the measure of the I<SUP>2.</SUP> An I<SUP>2</SUP> measurement greater than 50% would be taken to indicate substantial heterogeneity (<LINK REF="REF-Higgins-2011" TYPE="REFERENCE">Higgins 2011</LINK>).</P>
</HETEROGENEITY_ASSESSMENT>
<BIAS_ASSESSMENT MODIFIED="2013-08-06 03:00:14 +1200" MODIFIED_BY="[Empty name]">
<P>In order to avoid or at least minimise reporting biases (e.g. publication bias, multiple publication bias, language bias etc), we performed a comprehensive search for eligible studies and were alert for duplication of data. If there were 10 or more studies in an analysis, we planned to use a funnel plot to explore the possibility of small-study effects.</P>
</BIAS_ASSESSMENT>
<DATA_SYNTHESIS MODIFIED="2013-08-06 03:00:32 +1200" MODIFIED_BY="[Empty name]">
<P>It was our intention that if the studies were sufficiently similar, we would combine the data using a fixed-effect model</P>
<P>An increase in the odds of a particular outcome, which might be beneficial (e.g. live birth) or detrimental (e.g. adverse effects), would be displayed graphically in the meta-analyses to the right of the centre-line and a decrease in the odds of an outcome to the left of the centre-line. A fixed-effect analysis would be used if the underlying effect size was the same for all the trials in the analysis. If not, a random-effects analysis would be implemented.</P>
</DATA_SYNTHESIS>
<SUBGROUP_ANALYSIS MODIFIED="2013-08-06 03:00:56 +1200" MODIFIED_BY="[Empty name]">
<P>It was our intention that where data were available, we would conduct subgroup analyses to determine the separate evidence within the following subgroups:</P>
<OL>
<LI>average age for women of less than and over 35 years;</LI>
<LI>various types of subfertility;</LI>
<LI>different protocols for COH;</LI>
<LI>parity of women;</LI>
<LI>previous COH for IVF attempts.</LI>
</OL>
<P>If we had detected substantial heterogeneity, we would have explored possible explanations in sensitivity analyses. We would have taken any statistical heterogeneity into account when interpreting the results, especially if there were any variation in the direction of effect.<BR/>
</P>
</SUBGROUP_ANALYSIS>
<SENSITIVITY_ANALYSIS MODIFIED="2013-08-06 03:01:15 +1200" MODIFIED_BY="[Empty name]">
<P>It was our intention to conduct sensitivity analyses for the primary outcomes to determine whether the conclusions were robust to arbitrary decisions made regarding the eligibility and analysis. These analyses would have included consideration of whether the review conclusions would have differed if:</P>
<OL>
<LI>eligibility were restricted to studies without high risk of bias;</LI>
<LI>a random-effects model had been adopted;</LI>
<LI>alternative imputation strategies had been implemented;</LI>
<LI>the summary effect measure was risk ratio rather than odds ratio.</LI>
</OL>
</SENSITIVITY_ANALYSIS>
</DATA_COLLECTION>
</METHODS>
<RESULTS MODIFIED="2013-08-20 10:26:46 +1200" MODIFIED_BY="[Empty name]">
<STUDY_DESCRIPTION MODIFIED="2013-08-20 10:26:46 +1200" MODIFIED_BY="[Empty name]">
<SEARCH_RESULTS MODIFIED="2013-08-19 16:56:48 +1200" MODIFIED_BY="[Empty name]">
<P>See: <LINK TAG="CHARACTERISTICS_OF_EXCLUDED_STUDIES" TYPE="SECTION">Characteristics of excluded studies</LINK>; <LINK TAG="CHARACTERISTICS_OF_ONGOING_STUDIES" TYPE="SECTION">Characteristics of ongoing studies</LINK>
</P>
<P>
<I>Trial design characteristics</I>
</P>
<P>One hundred and twenty one articles were initially identified as providing data comparing conventional IVF with IVM in women with PCOS, of which 118 were excluded. Three ongoing trials were identified (<LINK REF="STD-Bruin-2010" TYPE="STUDY">Bruin 2010</LINK>; <LINK REF="STD-Massey-2010" TYPE="STUDY">Massey 2010</LINK>; <LINK REF="STD-Shavit-2012" TYPE="STUDY">Shavit 2012</LINK>).</P>
<P>Four further letters (and the appropriate reminders) were sent to the authors of the three ongoing studies (<LINK REF="STD-Bruin-2010" TYPE="STUDY">Bruin 2010</LINK>; <LINK REF="STD-Massey-2010" TYPE="STUDY">Massey 2010</LINK>; <LINK REF="STD-Shavit-2012" TYPE="STUDY">Shavit 2012</LINK>) and the study of <LINK REF="STD-Xu-2012" TYPE="STUDY">Xu 2012</LINK> for unpublished data, or regarding data before inclusion, as well as for details on methodology. We received answers from one of the ongoing, and from the study of <LINK REF="STD-Xu-2012" TYPE="STUDY">Xu 2012</LINK>, but the data provided did not allow us to include them in the current review.</P>
</SEARCH_RESULTS>
<INCLUDED_STUDIES_DESCR MODIFIED="2013-07-18 13:55:21 +1200" MODIFIED_BY="[Empty name]">
<P>No completed randomised controlled trials were found that met the inclusion criteria for the review.<BR/>
</P>
</INCLUDED_STUDIES_DESCR>
<EXCLUDED_STUDIES_DESCR MODIFIED="2013-08-20 10:26:46 +1200" MODIFIED_BY="[Empty name]">
<P>One hundred and eighteen studies were excluded. Sixty-five were excluded immediately based on the content of the available abstracts. Three papers were reviews or 'letters to the editor' which did not contain any original data.</P>
<P>Of the remaining 53 papers, 40 (<LINK REF="STD-Trounson-1994" TYPE="STUDY">Trounson 1994</LINK>; <LINK REF="STD-Barnes-1996" TYPE="STUDY">Barnes 1996</LINK>; <LINK REF="STD-Cha-1998" TYPE="STUDY">Cha 1998</LINK>; <LINK REF="STD-Beckers-1999" TYPE="STUDY">Beckers 1999</LINK>; <LINK REF="STD-Chian-1999" TYPE="STUDY">Chian 1999</LINK>; <LINK REF="STD-Cha-2000" TYPE="STUDY">Cha 2000</LINK>; <LINK REF="STD-Child-2001" TYPE="STUDY">Child 2001</LINK>; <LINK REF="STD-Child-2002" TYPE="STUDY">Child 2002</LINK>; <LINK REF="STD-Mikkelsen-2003" TYPE="STUDY">Mikkelsen 2003</LINK>; <LINK REF="STD-Lin-2003" TYPE="STUDY">Lin 2003</LINK>; <LINK REF="STD-Gulekli-2004" TYPE="STUDY">Gulekli 2004</LINK>; <LINK REF="STD-Le-Du-2005" TYPE="STUDY">Le Du 2005</LINK>; <LINK REF="STD-Li-2005" TYPE="STUDY">Li 2005</LINK>; <LINK REF="STD-Cha-2005" TYPE="STUDY">Cha 2005</LINK>; <LINK REF="STD-Soderstrom_x002d_Anttila-2005" TYPE="STUDY">Soderstrom-Anttila 2005</LINK>; <LINK REF="STD-Buckett-2005" TYPE="STUDY">Buckett 2005</LINK>; <LINK REF="STD-Son-2005" TYPE="STUDY">Son 2005</LINK>; <LINK REF="STD-Fukuda-2006" TYPE="STUDY">Fukuda 2006</LINK>; <LINK REF="STD-Lornage-2006" TYPE="STUDY">Lornage 2006</LINK>; <LINK REF="STD-Zhao-2006" TYPE="STUDY">Zhao 2006</LINK>; <LINK REF="STD-Sandraa-2006" TYPE="STUDY">Sandraa 2006</LINK>; <LINK REF="STD-Holzer-2006" TYPE="STUDY">Holzer 2006</LINK>; <LINK REF="STD-Shu_x002d_Shi-2006" TYPE="STUDY">Shu-Shi 2006</LINK>; <LINK REF="STD-Zhang-2007" TYPE="STUDY">Zhang 2007</LINK>; <LINK REF="STD-Buckett-2007" TYPE="STUDY">Buckett 2007</LINK>; <LINK REF="STD-Son-2007" TYPE="STUDY">Son 2007</LINK>; <LINK REF="STD-Buckett-2008" TYPE="STUDY">Buckett 2008</LINK>; <LINK REF="STD-Filali-2008" TYPE="STUDY">Filali 2008</LINK>; <LINK REF="STD-Zhao-2009" TYPE="STUDY">Zhao 2009</LINK>; <LINK REF="STD-Lim-2009" TYPE="STUDY">Lim 2009</LINK>; <LINK REF="STD-Benkhalifa-2009" TYPE="STUDY">Benkhalifa 2009</LINK>; <LINK REF="STD-Harris-2010" TYPE="STUDY">Harris 2010</LINK>; <LINK REF="STD-Liu-2010" TYPE="STUDY">Liu 2010</LINK>; <LINK REF="STD-Bos_x002d_Mikich-2011" TYPE="STUDY">Bos-Mikich 2011</LINK>; <LINK REF="STD-Gremeau-2012" TYPE="STUDY">Gremeau 2012</LINK>; <LINK REF="STD-Junk-2012" TYPE="STUDY">Junk 2012</LINK>; <LINK REF="STD-Roesner-2012" TYPE="STUDY">Roesner 2012</LINK>; <LINK REF="STD-Shalom_x002d_Paz-2012" TYPE="STUDY">Shalom-Paz 2012</LINK>; <LINK REF="STD-Xu-2012" TYPE="STUDY">Xu 2012</LINK>; <LINK REF="STD-Yu-2012" TYPE="STUDY">Yu 2012</LINK>) were retrieved but were subsequently excluded as being either prospective observational or retrospective studies (<I>see </I>
<LINK TAG="CHARACTERISTICS_OF_EXCLUDED_STUDIES" TYPE="SECTION">Characteristics of excluded studies</LINK>).</P>
<P>We identified ten RCTs (<LINK REF="STD-Chian-2000" TYPE="STUDY">Chian 2000</LINK>; <LINK REF="STD-Chung-2000" TYPE="STUDY">Chung 2000</LINK>; <LINK REF="STD-Mikkelsen-2001" TYPE="STUDY">Mikkelsen 2001</LINK>; <LINK REF="STD-Hreinsson-2003" TYPE="STUDY">Hreinsson 2003</LINK>; <LINK REF="STD-Ge-2008" TYPE="STUDY">Ge 2008</LINK>; <LINK REF="STD-Vieira-2008" TYPE="STUDY">Vieira 2008</LINK>; <LINK REF="STD-Vieira-2010" TYPE="STUDY">Vieira 2010</LINK>; <LINK REF="STD-Zheng-2012" TYPE="STUDY">Zheng 2012</LINK>; <LINK REF="STD-Walls-2012" TYPE="STUDY">Walls 2012</LINK>; <LINK REF="STD-Kim-2013" TYPE="STUDY">Kim 2013</LINK>) but none of these met our inclusion criteria. They compared different protocols of IVM in women with PCOS (differing in the administration of luteinising hormone (LH), follicle stimulating hormone (FSH), and HCG; the interval between FSH administration and IVM; and the use of different culture media) (<LINK REF="STD-Chian-2000" TYPE="STUDY">Chian 2000</LINK>; <LINK REF="STD-Chung-2000" TYPE="STUDY">Chung 2000</LINK>; <LINK REF="STD-Mikkelsen-2001" TYPE="STUDY">Mikkelsen 2001</LINK>; <LINK REF="STD-Hreinsson-2003" TYPE="STUDY">Hreinsson 2003</LINK>; <LINK REF="STD-Ge-2008" TYPE="STUDY">Ge 2008</LINK>; <LINK REF="STD-Zheng-2012" TYPE="STUDY">Zheng 2012</LINK>; <LINK REF="STD-Kim-2013" TYPE="STUDY">Kim 2013</LINK>) or compared IVM in PCOS and other causes of subfertility with regard to IVM rates (<LINK REF="STD-Vieira-2008" TYPE="STUDY">Vieira 2008</LINK>; <LINK REF="STD-Vieira-2010" TYPE="STUDY">Vieira 2010</LINK>) and IVF versus ICSI in IVM (<LINK REF="STD-Walls-2012" TYPE="STUDY">Walls 2012</LINK>) but not IVM versus conventional IVF or ICSI. Two were non-comparative case series (<LINK REF="STD-Barnes-1995" TYPE="STUDY">Barnes 1995</LINK>; <LINK REF="STD-Chian-2004" TYPE="STUDY">Chian 2004</LINK>). One study was described as an RCT (<LINK REF="STD-Choi-2012" TYPE="STUDY">Choi 2012</LINK>) from the study of the full text, but it was excluded after the e-mail communication with the corresponding author.</P>
</EXCLUDED_STUDIES_DESCR>
</STUDY_DESCRIPTION>
<STUDY_QUALITY MODIFIED="2013-07-08 17:16:00 +1200" MODIFIED_BY="[Empty name]">
<P>No studies were identified for inclusion.</P>
</STUDY_QUALITY>
<INTERVENTION_EFFECTS MODIFIED="2013-07-08 17:16:12 +1200" MODIFIED_BY="jane clarke">
<P>No studies were identified for inclusion; the review could not provide any results.</P>
</INTERVENTION_EFFECTS>
</RESULTS>
<DISCUSSION MODIFIED="2013-08-20 10:57:57 +1200" MODIFIED_BY="[Empty name]">
<P>In this 2013 update of the review, interpretation of results was still limited by the absence of randomised trials. However, in contrast to previous attempts, we found three ongoing studies. Nevertheless, any effect of in vitro maturation (IVM) relative to traditional in vitro fertilisation (IVF) in terms of live birth rates for women with polycystic ovarian syndrome (PCOS) still remains unknown.</P>
<P>Recovery of immature oocytes followed by IVM could be developed as a safe alternative method for the treatment of these women as their oocytes retain their maturational and developmental competence (<LINK REF="STD-Trounson-1994" TYPE="STUDY">Trounson 1994</LINK>), a procedure which was carried out successfully in a variety of different species during the previous century (<LINK REF="REF-Pincus-1935" TYPE="REFERENCE">Pincus 1935</LINK>; <LINK REF="REF-Edwards-1965" TYPE="REFERENCE">Edwards 1965</LINK>). During our search, we found some evidence that IVM could provide a promising alternative to conventional IVF or intracytoplasmic sperm injection (ICSI) in women with PCOS, especially to prevent ovarian hyperstimulation syndrome (OHSS), but it was not based on prospective randomised controlled trials. Observational studies showed a high maturation rate of the oocytes (up to 80.3%) (<LINK REF="STD-Child-2001" TYPE="STUDY">Child 2001</LINK>), fertilisation rates from 10% (<LINK REF="STD-Beckers-1999" TYPE="STUDY">Beckers 1999</LINK>) up to 76.5% (<LINK REF="STD-Child-2001" TYPE="STUDY">Child 2001</LINK>), clinical pregnancy rates from 21.5% (<LINK REF="STD-Cha-2005" TYPE="STUDY">Cha 2005</LINK>) to 50% per cycle (<LINK REF="STD-Holzer-2006" TYPE="STUDY">Holzer 2006</LINK>), implantation rates around 18% (<LINK REF="STD-Child-2002" TYPE="STUDY">Child 2002</LINK>; <LINK REF="STD-Holzer-2006" TYPE="STUDY">Holzer 2006</LINK>), live birth rates from 15.9% per retrieval (<LINK REF="STD-Child-2002" TYPE="STUDY">Child 2002</LINK>) to 33% per cycle (<LINK REF="STD-Holzer-2006" TYPE="STUDY">Holzer 2006</LINK>), and pregnancy complications at 13.2% (<LINK REF="STD-Cha-2005" TYPE="STUDY">Cha 2005</LINK>). Chromosomal abnormalities and outcomes were similar for IVM and conventional assisted reproductive technology (ART) populations (<LINK REF="STD-Buckett-2005" TYPE="STUDY">Buckett 2005</LINK>; <LINK REF="STD-Li-2005" TYPE="STUDY">Li 2005</LINK>). Case-control retrospective studies reported similar results with oocyte maturation rates up to 84% (<LINK REF="STD-Chian-2000" TYPE="STUDY">Chian 2000</LINK>), fertilisation rates from 43% (<LINK REF="STD-Soderstrom_x002d_Anttila-2005" TYPE="STUDY">Soderstrom-Anttila 2005</LINK>) to 70% (<LINK REF="STD-Le-Du-2005" TYPE="STUDY">Le Du 2005</LINK>), pregnancy rates from 22% (<LINK REF="STD-Sandraa-2006" TYPE="STUDY">Sandraa 2006</LINK>) to 55.6% (<LINK REF="STD-Fukuda-2006" TYPE="STUDY">Fukuda 2006</LINK>); while rates of miscarriage, ectopic pregnancy, and late fetal loss were similar for IVM and IVF or ICSI groups of women with PCOS (<LINK REF="STD-Buckett-2008" TYPE="STUDY">Buckett 2008</LINK>). Studies compared different protocols of IVM in women with PCOS. According to these, human chorionic gonadotrophin (HCG) priming, which was not dose-dependent (<LINK REF="STD-Gulekli-2004" TYPE="STUDY">Gulekli 2004</LINK>), raised the maturation rate from 69% to 84% (<LINK REF="STD-Chian-2000" TYPE="STUDY">Chian 2000</LINK>), fertilisation rate from 45% (<LINK REF="STD-Chung-2000" TYPE="STUDY">Chung 2000</LINK>) up to 80% (<LINK REF="STD-Ge-2008" TYPE="STUDY">Ge 2008</LINK>), pregnancy rate from 31% up to 38.5%, and live birth rate up to 33% (<LINK REF="STD-Ge-2008" TYPE="STUDY">Ge 2008</LINK>). FSH priming increased the pregnancy rate from 0% to 29% (<LINK REF="STD-Mikkelsen-2001" TYPE="STUDY">Mikkelsen 2001</LINK>).</P>
<P>In the absence of results of appropriate trials, we are unable to comment on the advantages or disadvantages of the technique. For the moment, we must await for the conclusions of the three ongoing studies on the technique and, furthermore, we wish to highlight the demand for properly designed randomised controlled trials (RCTs) in the field. There still exists a need to offer women with PCOS a promising alternative to conventional assisted reproduction procedures and IVM seems to be one. Moreover, adequate follow-up of trial participants in terms of neonatal and post-neonatal outcomes is necessary. Until such time as these data become available, a systematic review of observational studies could be considered to be the only source of data on the effects of IVM in women with PCOS.</P>
</DISCUSSION>
<CONCLUSIONS MODIFIED="2013-08-06 03:03:11 +1200" MODIFIED_BY="[Empty name]">
<IMPLICATIONS_PRACTICE MODIFIED="2013-08-06 03:03:03 +1200" MODIFIED_BY="[Empty name]">
<P>Data retrieved either from non-randomised comparisons of IVM and conventional ART and non-comparative case series, or from randomised trials comparing IVM protocols, show clearly that IVM is a feasible option for subfertile women with PCOS. Both favourable maturation, fertilisation, pregnancy, and live birth rates, but also pregnancy complications, including congenital anomalies have been reported with IVM similarly to those with conventional IVF or ICSI. Unfortunately, and unexpectedly, there are at present no data from randomised trials to support recommendations for clinical practice. On the other hand, there are three ongoing studies that have not reported their results as yet. Until more evidence is available, either from these last or from further well-designed RCTs in the field, IVM may not be the preferred first-line treatment for subfertile women with PCOS and it might be appropriate to continue to offer conventional ART.</P>
</IMPLICATIONS_PRACTICE>
<IMPLICATIONS_RESEARCH MODIFIED="2013-08-06 03:03:11 +1200" MODIFIED_BY="[Empty name]">
<P>We aimed to provide a clear overview of the differences between IVM and conventional IVF or ICSI so that women with PCOS could decide which treatment better suited their preferences. Unfortunately, we could not include any trial in this systematic review and hence, we could not come to any clear conclusions. Properly randomised studies with sufficient power and appropriate endpoints that compare IVM with conventional ART are urgently needed in women with PCOS and subfertility.<BR/>
</P>
</IMPLICATIONS_RESEARCH>
</CONCLUSIONS>
</BODY>
<ACKNOWLEDGEMENTS MODIFIED="2013-08-06 03:03:17 +1200" MODIFIED_BY="jane clarke">
<P>None.</P>
</ACKNOWLEDGEMENTS>
<CONFLICT_OF_INTEREST MODIFIED="2013-08-06 01:30:20 +1200" MODIFIED_BY="jane clarke">
<P>None known.</P>
</CONFLICT_OF_INTEREST>
<CONTRIBUTIONS MODIFIED="2013-08-20 10:51:03 +1200" MODIFIED_BY="[Empty name]">
<SUBSECTION>
<HEADING LEVEL="6">Contact author</HEADING>
<P>CS Siristatidis: wrote the protocol and the review and updated the review twice.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="6">Co-review authors</HEADING>
<P>Dr Abha Maheshwari: updated the initial protocol and made a major contribution to selection of studies.<BR/>Prof Siladitya Bhattacharya: initiated, corrected, and conceptualised the protocol and the review.<BR/>Dr Maria Creatsa: contributed to the 2013 update of the review.<BR/>Dr Nikos Vrachnis: contributed to the 2013 update of the review.</P>
</SUBSECTION>
</CONTRIBUTIONS>
<PRO_REV_DIFF MODIFIED="2013-08-06 02:03:44 +1200" MODIFIED_BY="[Empty name]">
<P>None.</P>
</PRO_REV_DIFF>
<PUBLIC_NOTES MODIFIED="2013-08-06 02:03:44 +1200" MODIFIED_BY="[Empty name]">
<P>None.</P>
</PUBLIC_NOTES>
</MAIN_TEXT>
<STUDIES_AND_REFERENCES MODIFIED="2013-09-03 12:01:13 +1200" MODIFIED_BY="[Empty name]">
<STUDIES MODIFIED="2013-09-03 12:01:13 +1200" MODIFIED_BY="[Empty name]">
<INCLUDED_STUDIES MODIFIED="2013-06-06 09:33:33 +1200" MODIFIED_BY="[Empty name]"/>
<EXCLUDED_STUDIES MODIFIED="2013-09-03 12:01:13 +1200" MODIFIED_BY="[Empty name]">
<STUDY DATA_SOURCE="PUB" ID="STD-Barnes-1995" MODIFIED="2011-03-11 13:28:52 +1300" MODIFIED_BY="[Empty name]" NAME="Barnes 1995" YEAR="">
<REFERENCE MODIFIED="2011-03-11 13:28:52 +1300" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Barnes FL, Crombie A, Gardner DK, Kausche A</AU>
<TI>Blastocyst development and birth after in-vitro maturation of human primary oocytes, intracytoplasmic sperm injection and assisted hatching</TI>
<SO>Human Reproduction</SO>
<YR>1995</YR>
<VL>10</VL>
<NO>12</NO>
<PG>3243-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Barnes-1996" MODIFIED="2008-09-20 00:08:04 +1200" MODIFIED_BY="[Empty name]" NAME="Barnes 1996" YEAR="1996">
<REFERENCE MODIFIED="2008-09-20 00:08:04 +1200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Barnes FL, Kausche A, Tiglias J, Wood C, Wilton L, Trounson A</AU>
<TI>Production of embryos from in vitro-matured primary human oocytes</TI>
<SO>Fertility and Sterility</SO>
<YR>1996</YR>
<VL>65</VL>
<NO>6</NO>
<PG>1151-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Beckers-1999" MODIFIED="2011-03-09 16:55:53 +1300" MODIFIED_BY="[Empty name]" NAME="Beckers 1999" YEAR="">
<REFERENCE MODIFIED="2011-03-09 16:55:53 +1300" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Beckers N, Pieters M, Ramos L, Zeilmaker G, Fauser B, Braat D</AU>
<TI>Retrieval, maturation, and fertilization of immature oocytes obtained from unstimulated patients with polycystic ovary syndrome</TI>
<SO>Journal of Assisted Reproduction and Genetics</SO>
<YR>1999</YR>
<VL>16</VL>
<NO>2</NO>
<PG>81-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Benkhalifa-2009" MODIFIED="2013-08-05 07:44:39 +1200" MODIFIED_BY="[Empty name]" NAME="Benkhalifa 2009" YEAR="2009">
<REFERENCE MODIFIED="2013-08-05 07:44:39 +1200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Benkhalifa M, Demirol A, Ménézo Y, Balashova E, Abduljalil AK, Abbas S, et al</AU>
<TI>Natural cycle IVF and oocyte in-vitro maturation in polycystic ovary syndrome: a collaborative prospective study</TI>
<SO>Reproductive Biomedicine Online</SO>
<YR>2009</YR>
<VL>18</VL>
<NO>1</NO>
<PG>29-36</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Bos_x002d_Mikich-2011" MODIFIED="2013-09-03 12:01:13 +1200" MODIFIED_BY="[Empty name]" NAME="Bos-Mikich 2011" YEAR="2010">
<REFERENCE MODIFIED="2013-09-03 12:01:13 +1200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Bos-Mikich A, Ferreira M, Höher M, Frantz G, Oliveira N, Dutra CG, et al</AU>
<TI>Fertilization outcome, embryo development and birth after un stimulated IVM</TI>
<SO>Journal of Assisted Reproduction and Genetics</SO>
<YR>2010</YR>
<VL>28</VL>
<NO>2</NO>
<PG>107-10</PG>
<IDENTIFIERS MODIFIED="2013-09-03 12:01:13 +1200" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Buckett-2005" MODIFIED="2008-09-20 00:09:05 +1200" MODIFIED_BY="[Empty name]" NAME="Buckett 2005" YEAR="2005">
<REFERENCE MODIFIED="2008-09-20 00:09:05 +1200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Buckett WM, Chian R, Holzer H, Usher R, Tan SL</AU>
<TI>Congenital abnormalities and perinatal outcome in pregnancies following IVM, IVF, and ICSI delivered in a single center</TI>
<SO>Fertility and Sterility</SO>
<YR>2005</YR>
<VL>84 Suppl 1</VL>
<PG>80-1</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="SOUGHT" ID="STD-Buckett-2007" MODIFIED="2013-05-27 07:01:12 +1200" MODIFIED_BY="[Empty name]" NAME="Buckett 2007" YEAR="2007">
<REFERENCE MODIFIED="2013-05-27 07:01:09 +1200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Buckett WM, Chian RC, Holzer H, Dean N, Usher R, Tan SL</AU>
<TI>Obstetric outcomes and congenital abnormalities after in vitro maturation, in vitro fertilization, and intracytoplasmic sperm injection</TI>
<SO>Obstetrics &amp; Gynecology</SO>
<YR>2007</YR>
<VL>110</VL>
<NO>4</NO>
<PG>885-91</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Buckett-2008" MODIFIED="2013-05-27 06:54:46 +1200" MODIFIED_BY="[Empty name]" NAME="Buckett 2008" YEAR="2008">
<REFERENCE MODIFIED="2013-05-27 06:52:33 +1200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Buckett WM, Chian RC, Dean N, Sylvestre C, Holzer H, Tan SL</AU>
<TI>Pregnancy loss in pregnancies conceived after in vitro oocyte maturation, conventional in vitro fertilization, and intracytoplasmic sperm injection</TI>
<SO>Fertility and Sterility</SO>
<YR>2008</YR>
<VL>110</VL>
<NO>4</NO>
<PG>885-91</PG>
<IDENTIFIERS MODIFIED="2013-05-27 06:52:33 +1200" MODIFIED_BY="jane clarke"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Cha-1998" MODIFIED="2008-05-05 13:02:48 +1200" MODIFIED_BY="jane clarke" NAME="Cha 1998" YEAR="1998">
<REFERENCE MODIFIED="2008-05-05 13:02:48 +1200" MODIFIED_BY="jane clarke" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Cha KY, Chian RC</AU>
<TI>Maturation in vitro of immature human oocytes for clinical use</TI>
<SO>Human Reproduction Update</SO>
<YR>1998</YR>
<VL>4</VL>
<NO>2</NO>
<PG>103-20</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Cha-2000" MODIFIED="2011-03-11 13:29:09 +1300" MODIFIED_BY="[Empty name]" NAME="Cha 2000" YEAR="2000">
<REFERENCE MODIFIED="2011-03-11 13:29:09 +1300" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Cha KY, Han SY, Chung HM, Choi DH</AU>
<TI>Pregnancies and deliveries after in vitro maturation culture followed by in vitro fertilization and embryo transfer without stimulation in women with polycystic ovary syndrome</TI>
<SO>Fertility and Sterility</SO>
<YR>2000</YR>
<VL>73</VL>
<NO>5</NO>
<PG>978-83</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Cha-2005" MODIFIED="2011-03-11 13:29:25 +1300" MODIFIED_BY="[Empty name]" NAME="Cha 2005" YEAR="2005">
<REFERENCE MODIFIED="2011-03-11 13:29:25 +1300" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Cha KY, Chung HM, Lee DR, Kwon H, Chung MK, Park LS, et al</AU>
<TI>Obstetric outcome of patients with polycystic ovary syndrome treated by in vitro maturation and in vitro fertilization-embryo transfer</TI>
<SO>Fertility and Sterility</SO>
<YR>2005</YR>
<VL>83</VL>
<PG>1461-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Chian-1999" MODIFIED="2013-08-05 07:52:58 +1200" MODIFIED_BY="[Empty name]" NAME="Chian 1999" YEAR="1999">
<REFERENCE MODIFIED="2013-08-05 07:52:58 +1200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Chian RC, Gulekli B, Buckett WM, Tan SL</AU>
<TI>Priming with human chorionic gonadotropin before retrieval of immature oocytes in women with infertility due to the polycystic ovary syndrome</TI>
<SO>New England Journal of Medicine</SO>
<YR>1999</YR>
<VL>341</VL>
<NO>21</NO>
<PG>1624-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Chian-2000" MODIFIED="2008-05-05 13:08:21 +1200" MODIFIED_BY="jane clarke" NAME="Chian 2000" YEAR="2000">
<REFERENCE MODIFIED="2008-05-05 13:08:21 +1200" MODIFIED_BY="jane clarke" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Chian RC, Buckett WM, Tulandi T, Tan SL</AU>
<TI>Prospective randomized study of human chorionic gonadotrophin priming before immature oocyte retrieval from unstimulated women with polycystic ovarian syndrome</TI>
<SO>Human Reproduction</SO>
<YR>2000</YR>
<VL>15</VL>
<NO>1</NO>
<PG>165-70</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Chian-2004" MODIFIED="2013-08-05 07:53:26 +1200" MODIFIED_BY="[Empty name]" NAME="Chian 2004" YEAR="2004">
<REFERENCE MODIFIED="2013-08-05 07:53:26 +1200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Chian RC, Buckett W, Jalil A, Son YU, Sylvestre C, Rao D, et al</AU>
<TI>Natural-cycle in vitro fertilization combined with in vitro maturation of immature oocytes is a potential approach in infertility treatment</TI>
<SO>Fertility and Sterility</SO>
<YR>2004</YR>
<VL>82</VL>
<NO>6</NO>
<PG>1675-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Child-2001" MODIFIED="2008-05-05 13:14:24 +1200" MODIFIED_BY="jane clarke" NAME="Child 2001" YEAR="2001">
<REFERENCE MODIFIED="2008-05-05 13:11:17 +1200" MODIFIED_BY="jane clarke" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Child TJ, Abdul-Jalil AK, Gulekli B, Tan SL</AU>
<TI>In vitro maturation and fertilization of oocytes from unstimulated normal ovaries, polycystic ovaries, and women with polycystic ovary syndrome</TI>
<SO>Fertility and Sterility</SO>
<YR>2001</YR>
<VL>76</VL>
<NO>5</NO>
<PG>936-42</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Child-2002" MODIFIED="2008-05-05 13:14:30 +1200" MODIFIED_BY="jane clarke" NAME="Child 2002" YEAR="2002">
<REFERENCE MODIFIED="2008-05-05 13:12:35 +1200" MODIFIED_BY="jane clarke" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Child TJ, Phillips SJ, Abdul-Jalil AK, Gulakli B, Tan SL</AU>
<TI>A comparison of in vitro maturation and in vitro fertilization for women with polycystic ovaries</TI>
<SO>Obstetrics and Gynecology</SO>
<YR>2002</YR>
<VL>100</VL>
<NO>4</NO>
<PG>665-70</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="MIX" ID="STD-Choi-2012" MODIFIED="2013-08-05 07:54:11 +1200" MODIFIED_BY="[Empty name]" NAME="Choi 2012" YEAR="2012">
<REFERENCE MODIFIED="2013-08-05 07:54:11 +1200" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Choi MH, Lee SH, Kim HO, Cha SH, Kim JY, Yang KM, et al</AU>
<TI>Comparison of assisted reproductive technology outcomes in infertile women with polycystic ovary syndrome: In vitro maturation, GnRH agonist, and GnRH antagonist cycles.</TI>
<SO>Clinical and Experimental Reproductive Medicine</SO>
<YR>2012</YR>
<VL>39</VL>
<NO>4</NO>
<PG>166-71</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Chung-2000" MODIFIED="2008-09-20 00:12:30 +1200" MODIFIED_BY="[Empty name]" NAME="Chung 2000" YEAR="2000">
<REFERENCE MODIFIED="2008-09-20 00:12:30 +1200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Chung MK, Chung HM, Lee WS, Han SY, Yoon TK, Cha KY</AU>
<TI>Applicability of a hCG priming of unstimulated PCOS patients for improving IVM/IVF-ET outcome</TI>
<SO>Fertility and Sterility</SO>
<YR>2000</YR>
<VL>74 Suppl 3</VL>
<PG>32-3</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Filali-2008" MODIFIED="2011-03-09 17:04:02 +1300" MODIFIED_BY="[Empty name]" NAME="Filali 2008" YEAR="2008">
<REFERENCE MODIFIED="2011-03-09 17:04:02 +1300" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Filali M, Hesters L, Fanchin R, Tachdjian G, Frydman R, Frydman N</AU>
<TI>Retrospective comparison of two media for invitro maturation of oocytes</TI>
<SO>Reproductive Biomedicine Online</SO>
<YR>2008</YR>
<VL>16</VL>
<NO>2</NO>
<PG>250-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Fukuda-2006" MODIFIED="2011-03-09 17:05:13 +1300" MODIFIED_BY="[Empty name]" NAME="Fukuda 2006" YEAR="2006">
<REFERENCE MODIFIED="2011-03-09 17:05:13 +1300" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Fukuda AI, Sato M, Sugihara K, Nagata F, Nakaoka Y, Morimoto Y</AU>
<TI>In vitro maturation, in vitro fertilisation and embryo transfer (IVM-IVF) combined with low dose FSH over metformin pretreatment and frozen-thawed cycles should be a routine ART option for polycystic ovarian syndrome (PCOS) patients</TI>
<SO>Fertility and Sterility</SO>
<YR>2006</YR>
<VL>86 Suppl 2</VL>
<PG>129</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Ge-2008" MODIFIED="2011-01-10 04:54:02 +1300" MODIFIED_BY="[Empty name]" NAME="Ge 2008" YEAR="2008">
<REFERENCE MODIFIED="2011-01-10 04:52:02 +1300" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ge HS, Huang XF, Zhang W, Zhao JZ, Lin JJ, Zhou WZ</AU>
<TI>Exposure to human chorionic gonadotropin during in vitro maturation does not improve the maturation rate and developmental potential of immature oocytes from patients with polycystic ovary syndrome</TI>
<SO>Fertility and Sterility</SO>
<YR>2008</YR>
<VL>89</VL>
<NO>1</NO>
<PG>98-103</PG>
<IDENTIFIERS MODIFIED="2011-01-10 04:52:02 +1300" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS MODIFIED="2011-01-10 04:54:02 +1300" MODIFIED_BY="[Empty name]"/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Gremeau-2012" MODIFIED="2013-08-05 07:55:16 +1200" MODIFIED_BY="[Empty name]" NAME="Gremeau 2012" YEAR="2012">
<REFERENCE MODIFIED="2013-08-05 07:55:16 +1200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Gremeau AS, Andreadis N, Fatum M, Craig J, Turner K, McVeigh E, et al</AU>
<TI>In vitro maturation or in vitro fertilization for women with polycystic ovaries? A case-control study of 194 treatment cycles</TI>
<SO>Fertility and Sterility</SO>
<YR>2012</YR>
<VL>98</VL>
<NO>2</NO>
<PG>355-60</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Gulekli-2004" MODIFIED="2008-05-05 13:55:39 +1200" MODIFIED_BY="jane clarke" NAME="Gulekli 2004" YEAR="2004">
<REFERENCE MODIFIED="2008-05-05 13:55:39 +1200" MODIFIED_BY="jane clarke" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Gulekli B, Buckett WM, Chian RC, Child TJ, Abdul-Jalil AK, Tan SL</AU>
<TI>Randomized, controlled trial of priming with 10,000 IU versus 20,000 IU of human chorionic gonadotropin in women with polycystic ovary syndrome who are undergoing in vitro maturation</TI>
<SO>Fertility and Sterility</SO>
<YR>2004</YR>
<VL>82</VL>
<NO>5</NO>
<PG>1458-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Harris-2010" MODIFIED="2011-01-10 00:08:41 +1300" MODIFIED_BY="[Empty name]" NAME="Harris 2010" YEAR="2010">
<REFERENCE MODIFIED="2011-01-09 23:51:19 +1300" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Harris SE, Maruthini D, Tang T, Balen AH, Picton HM</AU>
<TI>Metabolism and karyotype analysis of oocytes from patients with polycystic ovary syndrome</TI>
<SO>Human Reproduction</SO>
<YR>2010</YR>
<VL>25</VL>
<NO>9</NO>
<PG>2305-15</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Holzer-2006" MODIFIED="2008-05-05 13:56:39 +1200" MODIFIED_BY="jane clarke" NAME="Holzer 2006" YEAR="2006">
<REFERENCE MODIFIED="2008-05-05 13:56:39 +1200" MODIFIED_BY="jane clarke" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Holzer H, Scharf E, Chian RC, Demirtas E, Buckett W, Tan SL</AU>
<TI>In vitro maturation of oocytes collected from unstimulated ovaries for oocyte donation</TI>
<SO>Fertility and Sterility</SO>
<YR>2007</YR>
<VL>88</VL>
<NO>1</NO>
<PG>62-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Hreinsson-2003" MODIFIED="2013-08-05 07:57:26 +1200" MODIFIED_BY="jane clarke" NAME="Hreinsson 2003" YEAR="2003">
<REFERENCE MODIFIED="2013-08-05 07:57:26 +1200" MODIFIED_BY="jane clarke" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Hreinsson J, Rosenland B, Fridén B, Levkov L, Ek I, Suikkari AM, et al</AU>
<TI>Recombinant LH is equally effective as recombinant HCG in promoting oocyte maturation in a clinical in vitro maturation program: a randomised study</TI>
<SO>Human Reproduction</SO>
<YR>2003</YR>
<VL>18</VL>
<NO>10</NO>
<PG>2131-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Junk-2012" MODIFIED="2013-05-27 08:58:39 +1200" MODIFIED_BY="[Empty name]" NAME="Junk 2012" YEAR="2012">
<REFERENCE MODIFIED="2013-05-27 08:58:39 +1200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Junk SM, Yeap D</AU>
<TI>Improved implantation and ongoing pregnancy rates after single-embryo transfer with an optimized protocol for in vitro oocyte maturation in women with polycystic ovaries and polycystic ovary syndrome</TI>
<SO>Fertility and Sterility</SO>
<YR>2012</YR>
<VL>98</VL>
<NO>4</NO>
<PG>888-92</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kim-2013" MODIFIED="2013-08-19 16:50:08 +1200" MODIFIED_BY="[Empty name]" NAME="Kim 2013" YEAR="2013">
<REFERENCE MODIFIED="2013-08-19 16:50:08 +1200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kim MK, Park EA, Kim HJ, Choi WY, Cho JH, Lee WS, et al</AU>
<TI>Does supplementation of in-vitro culture medium with melatonin improve IVF outcome in PCOS?</TI>
<SO>Reproductive Biomedicine Online</SO>
<YR>2013</YR>
<VL>26</VL>
<NO>1</NO>
<PG>22-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Le-Du-2005" MODIFIED="2013-08-05 07:59:15 +1200" MODIFIED_BY="jane clarke" NAME="Le Du 2005" YEAR="2005">
<REFERENCE MODIFIED="2013-08-05 07:59:15 +1200" MODIFIED_BY="jane clarke" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Le Du A, Kadoch IJ, Bourcigaux N, Doumerc S, Bourrier MC, Chevalier N, et al</AU>
<TI>In vitro maturation for the treatment of infertility associated with polycystic ovarian syndrome: the French experience</TI>
<SO>Human Reproduction</SO>
<YR>2005</YR>
<VL>20</VL>
<NO>2</NO>
<PG>420-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Li-2005" MODIFIED="2008-09-20 00:14:17 +1200" MODIFIED_BY="[Empty name]" NAME="Li 2005" YEAR="2005">
<REFERENCE MODIFIED="2008-09-20 00:14:17 +1200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Li Y, Feng HL, Cao YJ, Zheng GJ, Yang Y, Mullen S, et al</AU>
<TI>Confocal microscopic analysis of the spindle and chromosome configurations of human oocytes matured in vitro</TI>
<SO>Fertility and Sterility</SO>
<YR>2006</YR>
<VL>85</VL>
<NO>4</NO>
<PG>827-32</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Lim-2009" MODIFIED="2013-07-19 14:33:26 +1200" MODIFIED_BY="[Empty name]" NAME="Lim 2009" YEAR="Fertility and Sterility">
<REFERENCE MODIFIED="2013-07-19 14:33:26 +1200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Lim JH, Yang SH, Xu Y, Yoon SH, Chian RC</AU>
<TI>Selection of patients for natural cycle in vitro fertilization combined with in vitro maturation of immature oocytes</TI>
<SO>Fertility and Sterility</SO>
<YR>2009</YR>
<VL>91</VL>
<NO>4</NO>
<PG>1050-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Lin-2003" MODIFIED="2013-08-05 08:00:31 +1200" MODIFIED_BY="[Empty name]" NAME="Lin 2003" YEAR="2003">
<REFERENCE MODIFIED="2013-08-05 08:00:31 +1200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Lin YH, Hwang JL, Huang LW, Mu SC, Seow KM, Chung J, et al</AU>
<TI>Combination of FSH priming and hCG priming for in-vitro maturation of human oocytes</TI>
<SO>Human Reproduction</SO>
<YR>2003</YR>
<VL>18</VL>
<NO>8</NO>
<PG>1632-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Liu-2010" MODIFIED="2011-01-10 00:18:26 +1300" MODIFIED_BY="[Empty name]" NAME="Liu 2010" YEAR="2010">
<REFERENCE MODIFIED="2011-01-10 00:18:22 +1300" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Liu S, Jiang JJ, Feng HL, Ma SY, Li M, Li Y</AU>
<TI>Evaluation of the immature human oocytes from unstimulated cycles in polycystic ovary syndrome patients using a novel scoring system</TI>
<SO>Fertility and Sterility</SO>
<YR>2010</YR>
<VL>93</VL>
<NO>7</NO>
<PG>2202-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Lornage-2006" MODIFIED="2013-06-02 23:02:32 +1200" MODIFIED_BY="[Empty name]" NAME="Lornage 2006" YEAR="2006">
<REFERENCE MODIFIED="2013-06-02 23:02:32 +1200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Lornage J</AU>
<TI>In vitro maturation: the French experience</TI>
<SO>Journal de Gynécologie, Obstétrique et Biologie de la Reproduction (Paris)</SO>
<YR>2006</YR>
<VL>35(5 Pt 2)</VL>
<PG>2S3-2S7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Mikkelsen-2001" MODIFIED="2008-05-05 14:03:05 +1200" MODIFIED_BY="jane clarke" NAME="Mikkelsen 2001" YEAR="2001">
<REFERENCE MODIFIED="2008-05-05 14:03:05 +1200" MODIFIED_BY="jane clarke" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Mikkelsen AL, Lindenberg S</AU>
<TI>Benefit of FSH priming of women with PCOS to the in vitro maturation procedure and the outcome: A randomized prospective study</TI>
<SO>Reproduction</SO>
<YR>2001</YR>
<VL>122</VL>
<NO>4</NO>
<PG>587-92</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Mikkelsen-2003" MODIFIED="2011-03-09 17:06:37 +1300" MODIFIED_BY="[Empty name]" NAME="Mikkelsen 2003" YEAR="2003">
<REFERENCE MODIFIED="2011-03-09 17:06:37 +1300" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Mikkelsen AL, Host E, Blaabjerg J, Lindenberg S</AU>
<TI>Time interval between FSH priming and aspiration of immature human oocytes for in vitro maturation: a prospective randomised study</TI>
<SO>Reproductive Biomedicine Online</SO>
<YR>2003</YR>
<VL>6</VL>
<NO>4</NO>
<PG>416-20</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Roesner-2012" MODIFIED="2013-06-02 08:30:43 +1200" MODIFIED_BY="[Empty name]" NAME="Roesner 2012" YEAR="2012">
<REFERENCE MODIFIED="2013-06-02 08:30:37 +1200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Roesner S, Von Wolff M, Eberhardt I, Beuter-Winkler P, Toth B, Strowitzki T</AU>
<TI>In vitro maturation: a five-year experience</TI>
<SO>Acta Obstetricia et Gynecologica Scandinavica</SO>
<YR>2012</YR>
<VL>91</VL>
<NO>1</NO>
<PG>22-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Sandraa-2006" MODIFIED="2008-09-20 00:15:44 +1200" MODIFIED_BY="[Empty name]" NAME="Sandraa 2006" YEAR="2006">
<REFERENCE MODIFIED="2008-09-20 00:15:44 +1200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Sandraa P, Cheloa E, Cuomoa S, Livia C</AU>
<TI>IVM is a promising alternative to conventional IVF treatment for women with polycystic ovarian syndrome (PCOS)</TI>
<SO>Fertility and Sterility</SO>
<YR>2006</YR>
<VL>86 Suppl 3</VL>
<PG>128</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Shalom_x002d_Paz-2012" MODIFIED="2013-05-27 09:02:06 +1200" MODIFIED_BY="[Empty name]" NAME="Shalom-Paz 2012" YEAR="2012">
<REFERENCE MODIFIED="2013-05-27 09:02:04 +1200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Shalom-Paz E, Holzer H, Son W, Levin I, Tan SL, Almog B</AU>
<TI>PCOS patients can benefit from in vitro maturation (IVM) of oocytes</TI>
<SO>European Journal of Obstetrics, Gynecology and Reproductive Biology</SO>
<YR>2012</YR>
<VL>165</VL>
<NO>1</NO>
<PG>53-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Shu_x002d_Shi-2006" MODIFIED="2008-05-05 14:06:16 +1200" MODIFIED_BY="jane clarke" NAME="Shu-Shi 2006" YEAR="2006">
<REFERENCE MODIFIED="2008-05-05 14:06:16 +1200" MODIFIED_BY="jane clarke" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Shu-Chi M, Jiann-Loung H, Yu-Hung L, Tseng-Chen S, Ming-I L, Tsu-Fuh Y</AU>
<TI>Growth and development of children conceived by in-vitro maturation of human oocytes</TI>
<SO>Early Human Development</SO>
<YR>2006</YR>
<VL>82</VL>
<NO>10</NO>
<PG>677-82</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Soderstrom_x002d_Anttila-2005" MODIFIED="2008-10-29 09:39:20 +1300" MODIFIED_BY="jane clarke" NAME="Soderstrom-Anttila 2005" YEAR="2005">
<REFERENCE MODIFIED="2008-05-05 14:38:46 +1200" MODIFIED_BY="jane clarke" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Soderstrom-Anttila V, Makinen S, Tuuri T, Suikkari AM</AU>
<TI>Favourable pregnancy results with insemination of in vitro matured oocytes from unstimulated patients</TI>
<SO>Human Reproduction</SO>
<YR>2005</YR>
<VL>20</VL>
<NO>6</NO>
<PG>1534-40</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Son-2005" MODIFIED="2008-09-20 00:16:19 +1200" MODIFIED_BY="[Empty name]" NAME="Son 2005" YEAR="2005">
<REFERENCE MODIFIED="2008-09-20 00:16:19 +1200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Son WY, Lee SY, Lim JH</AU>
<TI>Fertilization, cleavage and blastocyst development according to the maturation timing of oocytes in in vitro maturation cycles</TI>
<SO>Human Reproduction</SO>
<YR>2005</YR>
<VL>20</VL>
<NO>11</NO>
<PG>3204-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Son-2007" MODIFIED="2013-08-05 08:02:26 +1200" MODIFIED_BY="[Empty name]" NAME="Son 2007" YEAR="2007">
<REFERENCE MODIFIED="2013-08-05 08:02:26 +1200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Son WY, Lee SY, Yoon SH, Lim JH</AU>
<TI>Pregnancies and deliveries after transfer of human blastocysts derived from in vitro matured oocytes in in vitro maturation cycles</TI>
<SO>Fertility and Sterility</SO>
<YR>2007</YR>
<VL>87</VL>
<NO>6</NO>
<PG>1491-3</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Trounson-1994" MODIFIED="2008-05-05 14:10:06 +1200" MODIFIED_BY="jane clarke" NAME="Trounson 1994" YEAR="1994">
<REFERENCE MODIFIED="2008-05-05 14:10:06 +1200" MODIFIED_BY="jane clarke" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Trounson A, Wood C, Kausche A</AU>
<TI>In vitro maturation and the fertilization and developmental competence of oocytes recovered from untreated polycystic ovarian patients</TI>
<SO>Fertility and Sterility</SO>
<YR>1994</YR>
<VL>62</VL>
<NO>2</NO>
<PG>353-62</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Vieira-2008" MODIFIED="2013-08-05 08:02:55 +1200" MODIFIED_BY="[Empty name]" NAME="Vieira 2008" YEAR="2008">
<REFERENCE MODIFIED="2013-08-05 08:02:55 +1200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Vieira RC, Barcelos ID, Ferreira EM, de Araújo MC, dos Reis RM, Ferriani RA, et al</AU>
<TI>Evaluation of meiotic abnormalities of oocytes from polycystic ovary syndrome patients submitted to ovarian stimulation</TI>
<SO>Revista Brasileira de Ginecologia e Obstetrícia</SO>
<YR>2008</YR>
<VL>30</VL>
<NO>5</NO>
<PG>241-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Vieira-2010" MODIFIED="2011-03-11 13:17:17 +1300" MODIFIED_BY="[Empty name]" NAME="Vieira 2010" YEAR="2010">
<REFERENCE MODIFIED="2011-03-11 13:17:17 +1300" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>Vieira RC, Barcelos ID, Ferreira EM, Martins WP, Ferriani RA, Navarro PA</AU>
<TI>Spindle and chromosome configurations of in vitro-matured oocytes from polycystic ovary syndrome and ovulatory infertile women: a pilot study</TI>
<SO>Journal of Assisted Reproduction and Genetics</SO>
<YR>2010</YR>
<VL>E publication ahead of print</VL>
<IDENTIFIERS MODIFIED="2011-03-11 13:16:55 +1300" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2011-03-11 13:16:55 +1300" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE=" 10.1007/s10815-010-9475-7"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Walls-2012" MODIFIED="2013-08-19 16:30:10 +1200" MODIFIED_BY="[Empty name]" NAME="Walls 2012" YEAR="2012">
<REFERENCE MODIFIED="2013-08-19 16:30:10 +1200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Walls M, Junk S, Ryan JP, Hart R</AU>
<TI>IVF versus ICSI for the fertilization of in-vitro matured human oocytes</TI>
<SO>Reproductive Biomedicine Online</SO>
<YR>2012</YR>
<VL>25</VL>
<NO>6</NO>
<PG>603-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Xu-2012" MODIFIED="2013-08-05 08:03:19 +1200" MODIFIED_BY="[Empty name]" NAME="Xu 2012" YEAR="2012">
<REFERENCE MODIFIED="2013-08-05 08:03:19 +1200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Xu YP, Xiang HF, Zou WW, Li ZL, Zhang ZG, Zhou P, et al</AU>
<TI>Clinical application of in vitro maturation of human immature oocytes for infertile women with polycystic ovary syndrome</TI>
<SO>Zhonghua Fu Chan Ke Za Zhi</SO>
<YR>2012</YR>
<VL>47</VL>
<NO>1</NO>
<PG>14-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Yu-2012" MODIFIED="2013-05-27 09:08:01 +1200" MODIFIED_BY="[Empty name]" NAME="Yu 2012" YEAR="2012">
<REFERENCE MODIFIED="2013-05-27 09:07:57 +1200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Yu R, Lin J, Zhao JZ, Wang PY, Xiao SQ, Zhang W</AU>
<TI>Study on clinical effect on infertility women with polycystic ovary syndrome treated by in vitro maturation and in vitro fertilization-embryo transfer</TI>
<SO>Zhonghua Fu Chan Ke Za Zhi</SO>
<YR>2012</YR>
<VL>47</VL>
<NO>4</NO>
<PG>250-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Zhang-2007" MODIFIED="2011-03-09 17:07:51 +1300" MODIFIED_BY="[Empty name]" NAME="Zhang 2007" YEAR="2007">
<REFERENCE MODIFIED="2011-03-09 17:07:51 +1300" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Zhang ZG, Zhao JH, Wei ZL, Cong L, Zhou P, Cao YX</AU>
<TI>Human umbilical cord blood serum in culture medium on oocyte maturation In vitro</TI>
<SO>Archives of Andrology</SO>
<YR>2007</YR>
<VL>53</VL>
<NO>6</NO>
<PG>303-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Zhao-2006" MODIFIED="2013-08-05 08:03:55 +1200" MODIFIED_BY="jane clarke" NAME="Zhao 2006" YEAR="2006">
<REFERENCE MODIFIED="2013-08-05 08:03:55 +1200" MODIFIED_BY="jane clarke" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Zhao JZ, Ge HS, Ye BL, Huang XF, Zhou HW, Chi HH, et al</AU>
<TI>In vitro maturation and fertilization of unstimulated immature oocyte for the treatment of infertile women</TI>
<SO>Zhonghua Fu Chan Ke Za Zhi</SO>
<YR>2006</YR>
<VL>41</VL>
<NO>3</NO>
<PG>173-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Zhao-2009" MODIFIED="2011-03-09 17:08:47 +1300" MODIFIED_BY="[Empty name]" NAME="Zhao 2009" YEAR="2009">
<REFERENCE MODIFIED="2011-03-09 17:08:47 +1300" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Zhao JZ, Chen X, Wang PY, Zhou W, Lin JJ, Zhang W, et al</AU>
<TI>Outcome of pregnancy in women with polycystic ovary syndrome treated by in vitro maturation of immature oocytes</TI>
<SO>Zhonghua Fu Chan Ke Za Zhi</SO>
<YR>2009</YR>
<VL>44</VL>
<NO>6</NO>
<PG>409-12</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Zheng-2012" MODIFIED="2013-08-19 16:43:39 +1200" MODIFIED_BY="[Empty name]" NAME="Zheng 2012" YEAR="2012">
<REFERENCE MODIFIED="2013-08-19 16:43:39 +1200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Zheng X, Wang L, Zhen X, Lian Y, Liu P, Qiao J</AU>
<TI>Effect of hCG priming on embryonic development of immature oocytes collected from unstimulated women with polycystic ovarian syndrome</TI>
<SO>Reproductive Biology and Endocrinology</SO>
<YR>2012</YR>
<VL>10</VL>
<PG>40</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</EXCLUDED_STUDIES>
<AWAITING_STUDIES MODIFIED="2013-05-27 04:29:18 +1200" MODIFIED_BY="[Empty name]"/>
<ONGOING_STUDIES MODIFIED="2013-08-05 20:15:24 +1200" MODIFIED_BY="[Empty name]">
<STUDY DATA_SOURCE="PUB" ID="STD-Bruin-2010" MODIFIED="2013-07-19 14:41:29 +1200" MODIFIED_BY="[Empty name]" NAME="Bruin 2010" YEAR="2010">
<REFERENCE MODIFIED="2013-07-19 14:41:29 +1200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="UNPUBLISHED">
<AU>Bruin JP</AU>
<TI>A multicentre randomised controlled trial comparing in vitro maturation of oocytes with in vitro fertilisation in women with an increased risk of ovarian hyperstimulation syndrome</TI>
<SO>http://www.trialregister.nl/trialreg/admin/rctview.asp?TC=2375/61229302 ISRCT</SO>
<YR>2010</YR>
<IDENTIFIERS MODIFIED="2013-07-19 14:41:22 +1200" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2013-07-19 14:41:22 +1200" MODIFIED_BY="[Empty name]" TYPE="OTHER" VALUE="http://www.trialregister.nl/trialreg/admin/rctview.asp?TC=2375/61229302 ISRCTN"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Massey-2010" MODIFIED="2013-08-05 20:15:24 +1200" MODIFIED_BY="[Empty name]" NAME="Massey 2010" YEAR="2010">
<REFERENCE MODIFIED="2013-08-05 08:05:27 +1200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="UNPUBLISHED">
<AU>Massey JB</AU>
<TI>In vitro maturation with in vitro fertilization (IVF) compared to nild in vitro fertilization (IVM vs IVF)</TI>
<SO>http://clinicaltrials.gov/show/NCT00867763</SO>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS MODIFIED="2013-08-05 20:15:24 +1200" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2013-05-27 08:41:03 +1200" MODIFIED_BY="[Empty name]" TYPE="OTHER" VALUE="ClinicalTrials.gov Identifier:NCT00867763"/>
</IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Shavit-2012" MODIFIED="2013-08-05 08:06:21 +1200" MODIFIED_BY="[Empty name]" NAME="Shavit 2012" YEAR="2012">
<REFERENCE MODIFIED="2013-08-05 08:06:21 +1200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="UNPUBLISHED">
<AU>Shavit T</AU>
<TI>Comparison between two fertility protocols in obese polycystic ovary syndrome patients</TI>
<SO>ClinicalTrials.gov Identifier:NCT01473459</SO>
<IDENTIFIERS MODIFIED="2013-07-19 14:40:30 +1200" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2013-07-19 14:40:30 +1200" MODIFIED_BY="[Empty name]" TYPE="OTHER" VALUE="ClinicalTrials.gov Identifier:NCT01473459"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</ONGOING_STUDIES>
</STUDIES>
<OTHER_REFERENCES MODIFIED="2013-08-19 16:50:08 +1200" MODIFIED_BY="[Empty name]">
<ADDITIONAL_REFERENCES MODIFIED="2013-08-19 16:50:08 +1200" MODIFIED_BY="[Empty name]">
<REFERENCE ID="REF-Archer-2004" MODIFIED="2013-08-05 08:07:35 +1200" MODIFIED_BY="[Empty name]" NAME="Archer 2004" TYPE="JOURNAL_ARTICLE">
<AU>Archer J, Chang J</AU>
<TI>Hirsutism and acne in polycystic ovary syndrome</TI>
<SO>Best Practice &amp; Research Clinical Obstetrics &amp; Gynaecology</SO>
<YR>2004</YR>
<VL>18</VL>
<NO>5</NO>
<PG>737-54</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Azziz-2005" MODIFIED="2013-08-05 20:15:57 +1200" MODIFIED_BY="[Empty name]" NAME="Azziz 2005" TYPE="JOURNAL_ARTICLE">
<AU>Azziz R, Marin C, Hoq L, Badamgarav E, Song P</AU>
<TI>Health care-related economic burden of the polycystic ovary syndrome during the reproductive life span</TI>
<SO>Journal of Clinical Endocrinology &amp; Metabolism</SO>
<YR>2005</YR>
<VL>90</VL>
<NO>8</NO>
<PG>4650-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Cakmak-2011" MODIFIED="2013-05-26 20:56:15 +1200" MODIFIED_BY="[Empty name]" NAME="Cakmak 2011" TYPE="JOURNAL_ARTICLE">
<AU>Cakmak H, Taylor HS</AU>
<TI>Implantation failure: molecular mechanisms and clinical treatment</TI>
<SO>Human Reproduction Update</SO>
<YR>2011</YR>
<VL>17</VL>
<NO>2</NO>
<PG>242-53</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-de-Ziegler-2012" MODIFIED="2013-05-27 07:53:37 +1200" MODIFIED_BY="[Empty name]" NAME="de Ziegler 2012" TYPE="JOURNAL_ARTICLE">
<AU>de Ziegler D, Streuli I, Gayet V, Frydman N, Bajouh O, Chapron C</AU>
<TI>Retrieving oocytes from small non-stimulated follicles in polycystic ovary syndrome (PCOS): in vitro maturation (IVM) is not indicated in the new GnRH antagonist era</TI>
<SO>Fertility and Sterility</SO>
<YR>2012</YR>
<VL>98</VL>
<NO>2</NO>
<PG>290-3</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Dewailly-2011" MODIFIED="2013-08-05 20:16:33 +1200" MODIFIED_BY="[Empty name]" NAME="Dewailly 2011" TYPE="JOURNAL_ARTICLE">
<AU>Dewailly D, Gronier H, Poncelet E, Robin G, Leroy M, Pigny P, et al</AU>
<TI>Diagnosis of polycystic ovary syndrome (PCOS): revisiting the threshold values of follicle count on ultrasound and of the serum AMH level for the definition of polycystic ovaries</TI>
<SO>Human Reproduction</SO>
<YR>2011</YR>
<VL>26</VL>
<NO>11</NO>
<PG>3123-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Edwards-1965" MODIFIED="2008-05-05 14:14:07 +1200" MODIFIED_BY="jane clarke" NAME="Edwards 1965" TYPE="JOURNAL_ARTICLE">
<AU>Edwards RG</AU>
<TI>Maturation in vitro of mouse, sheep, cow, pig, rhesus monkey and human ovarian oocytes</TI>
<SO>Nature</SO>
<YR>1965</YR>
<VL>208</VL>
<PG>349-51</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-ESHRE_x002f_ASRM-2003" MODIFIED="2008-05-12 13:28:39 +1200" MODIFIED_BY="jane clarke" NAME="ESHRE/ASRM 2003" TYPE="JOURNAL_ARTICLE">
<AU>The Rotterdam ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group</AU>
<TI>Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome</TI>
<SO>Fertility and Sterility</SO>
<YR>2003</YR>
<VL>81</VL>
<PG>19-25</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Fadini-2009" MODIFIED="2013-08-05 20:17:01 +1200" MODIFIED_BY="[Empty name]" NAME="Fadini 2009" TYPE="JOURNAL_ARTICLE">
<AU>Fadini R, Dal Canto MB, Renzini MM, Brambillasca F, Comi R, Fumagalli D, et al</AU>
<TI>Predictive factors in in-vitro maturation in unstimulated women with normal ovaries</TI>
<SO>Reproductive Biomedicine Online</SO>
<YR>2009</YR>
<VL>18</VL>
<NO>2</NO>
<PG>251-61</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Fadini-2013" MODIFIED="2013-08-05 20:17:35 +1200" MODIFIED_BY="[Empty name]" NAME="Fadini 2013" TYPE="JOURNAL_ARTICLE">
<AU>Fadini R, Mignini Renzini M, Dal Canto M, Epis A, Crippa M, Caliari I, et al</AU>
<TI>Oocyte in vitro maturation in normo-ovulatory women</TI>
<SO>Fertility and Sterility</SO>
<YR>2013</YR>
<VL>99</VL>
<NO>5</NO>
<PG>1162-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Heijnen-2006" MODIFIED="2013-08-05 20:17:51 +1200" MODIFIED_BY="[Empty name]" NAME="Heijnen 2006" TYPE="JOURNAL_ARTICLE">
<AU>Heijnen EM, Eijkemans MJ, Hughes EG, Laven JS, Macklon NS, Fauser BC</AU>
<TI>A meta-analysis of outcomes of conventional IVF in women with polycysticovary syndrome</TI>
<SO>Human Reproduction Update</SO>
<YR>2006</YR>
<VL>12</VL>
<NO>1</NO>
<PG>13&#8211;21</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Higgins-2011" MODIFIED="2013-08-05 20:18:05 +1200" MODIFIED_BY="[Empty name]" NAME="Higgins 2011" TYPE="OTHER">
<AU>Higgins JPT, Green S (editors)</AU>
<TI>Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]</TI>
<SO>Available from www.cochrane-handbook.org</SO>
<YR>2011</YR>
<ED>The Cochrane Collaboration</ED>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Liu-2003" MODIFIED="2008-05-05 14:20:43 +1200" MODIFIED_BY="jane clarke" NAME="Liu 2003" TYPE="JOURNAL_ARTICLE">
<AU>Liu JY, Qian Y, Mao YD, Ding W, Ynag NM</AU>
<TI>In vitro maturation, fertilization and embryo transfer of human immature oocyte</TI>
<SO>Zhonghua Fu Chan Ke Za Zhi</SO>
<YR>2003</YR>
<VL>38</VL>
<NO>4</NO>
<PG>230-2</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-MacDougall-1993" MODIFIED="2008-05-05 14:22:38 +1200" MODIFIED_BY="jane clarke" NAME="MacDougall 1993" TYPE="JOURNAL_ARTICLE">
<AU>MacDougall MJ, Tan SL, Balen A, Jacobs HS</AU>
<TI>A controlled study comparing patients with and without polycystic ovaries undergoing in-vitro fertilization</TI>
<SO>Human Reproduction</SO>
<YR>1993</YR>
<VL>8</VL>
<NO>2</NO>
<PG>233-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Mikkelsen-2005" MODIFIED="2013-05-27 06:49:10 +1200" MODIFIED_BY="[Empty name]" NAME="Mikkelsen 2005" TYPE="JOURNAL_ARTICLE">
<AU>Mikkelsen AL</AU>
<TI>Strategies in human in-vitro maturation and their clinical outcome</TI>
<SO>Reproductive Biomedicine Online</SO>
<YR>2005</YR>
<VL>10</VL>
<NO>5</NO>
<PG>593-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Nagy-1996" MODIFIED="2008-05-12 13:20:44 +1200" MODIFIED_BY="jane clarke" NAME="Nagy 1996" TYPE="JOURNAL_ARTICLE">
<AU>Nagy ZP, Cecile J, Liu J, Loccufier A, Devroey P, Van Steirteghem A</AU>
<TI>Pregnancy and birth after intracytoplasmic sperm injection of in vitro matured germinal-vesicle stage oocytes: case report</TI>
<SO>Fertility and Sterility</SO>
<YR>1996</YR>
<VL>65</VL>
<NO>5</NO>
<PG>1047-50</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-NICE-2004" MODIFIED="2008-09-20 00:17:58 +1200" MODIFIED_BY="[Empty name]" NAME="NICE 2004" TYPE="OTHER">
<AU>National Collaborating Centre for Women's and Children's Health / National Institute for Clinical Excellence</AU>
<TI>Fertility: assessment and treatment for people with fertility problems</TI>
<SO>RCOG Press</SO>
<YR>2004</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Pincus-1935" MODIFIED="2008-05-05 14:26:43 +1200" MODIFIED_BY="jane clarke" NAME="Pincus 1935" TYPE="JOURNAL_ARTICLE">
<AU>Pincus G, Enzmann EV</AU>
<TI>The comparative behaviour of mammalian eggs in vivo and in vitro</TI>
<SO>Journal of Experimental Medicine</SO>
<YR>1935</YR>
<VL>62</VL>
<PG>665-75</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Qiao-2011" MODIFIED="2013-05-26 20:52:13 +1200" MODIFIED_BY="[Empty name]" NAME="Qiao 2011" TYPE="JOURNAL_ARTICLE">
<AU>Qiao J, Feng HL</AU>
<TI>Extra- and intra-ovarian factors in polycystic ovary syndrome: impact on oocyte maturation and embryo developmental competence</TI>
<SO>Human Reproduction Update</SO>
<YR>2011</YR>
<VL>17</VL>
<NO>1</NO>
<PG>17-33</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Son-2010" MODIFIED="2013-05-26 20:22:31 +1200" MODIFIED_BY="[Empty name]" NAME="Son 2010" TYPE="JOURNAL_ARTICLE">
<AU>Son WY, Tan SL</AU>
<TI>Laboratory and embryological aspects of hCG-primed in vitro maturation cycles for patients with polycystic ovaries</TI>
<SO>Human Reproduction Update</SO>
<YR>2010</YR>
<VL>16</VL>
<NO>6</NO>
<PG>675-89</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Suikkari-2008" MODIFIED="2013-05-27 08:24:13 +1200" MODIFIED_BY="[Empty name]" NAME="Suikkari 2008" TYPE="JOURNAL_ARTICLE">
<AU>Suikkari AM</AU>
<TI>In-vitro maturation: its role in fertility treatment</TI>
<SO>Current Opinion in Obstetrics and Gynecology</SO>
<YR>2008</YR>
<VL>20</VL>
<NO>3</NO>
<PG>242-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Trounson-2001" MODIFIED="2008-05-05 14:30:35 +1200" MODIFIED_BY="jane clarke" NAME="Trounson 2001" TYPE="JOURNAL_ARTICLE">
<AU>Trounson A, Anderiesz C, Jones G</AU>
<TI>Maturation of human oocytes in vitro and their developmental competence</TI>
<SO>Reproduction</SO>
<YR>2001</YR>
<VL>121</VL>
<NO>1</NO>
<PG>51-75</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Yoon-2001" MODIFIED="2013-08-05 20:19:46 +1200" MODIFIED_BY="jane clarke" NAME="Yoon 2001" TYPE="JOURNAL_ARTICLE">
<AU>Yoon HG, Yoon SH, Son WY, Lee SW, Park SP, Im KS, et al</AU>
<TI>Pregnancies resulting from in vitro matured oocytes collected from women with regular menstrual cycle</TI>
<SO>Journal of Assisted Reproduction and Genetics</SO>
<YR>2001</YR>
<VL>18</VL>
<NO>6</NO>
<PG>325-9</PG>
<IDENTIFIERS/>
</REFERENCE>
</ADDITIONAL_REFERENCES>
<OTHER_VERSIONS_REFERENCES MODIFIED="2013-08-19 16:14:45 +1200" MODIFIED_BY="[Empty name]">
<REFERENCE ID="REF-Siristatidis-2009" MODIFIED="2013-08-19 16:14:45 +1200" MODIFIED_BY="[Empty name]" NAME="Siristatidis 2009" TYPE="COCHRANE_REVIEW">
<AU>Siristatidis CS, Maheshwari A, Bhattacharya S</AU>
<TI>In vitro maturation in subfertile women with polycystic ovarian syndrome undergoing assisted reproduction</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2009</YR>
<NO>1</NO>
<IDENTIFIERS MODIFIED="2013-07-19 14:39:10 +1200" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2013-07-19 14:39:10 +1200" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1002/14651858.CD006606.pub2"/>
</IDENTIFIERS>
</REFERENCE>
</OTHER_VERSIONS_REFERENCES>
<PENDING_REFERENCES/>
</OTHER_REFERENCES>
</STUDIES_AND_REFERENCES>
<CHARACTERISTICS_OF_STUDIES MODIFIED="2013-08-19 16:55:07 +1200" MODIFIED_BY="[Empty name]">
<CHARACTERISTICS_OF_INCLUDED_STUDIES MODIFIED="2013-06-06 09:33:33 +1200" MODIFIED_BY="[Empty name]" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<FOOTNOTES/>
</CHARACTERISTICS_OF_INCLUDED_STUDIES>
<CHARACTERISTICS_OF_EXCLUDED_STUDIES MODIFIED="2013-08-19 16:55:07 +1200" MODIFIED_BY="[Empty name]" SORT_BY="STUDY">
<EXCLUDED_CHAR MODIFIED="2011-03-11 13:27:51 +1300" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Barnes-1995">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2011-03-11 13:27:51 +1300" MODIFIED_BY="[Empty name]">
<P>Case report</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-06-06 09:34:21 +1200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Barnes-1996">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-06-06 09:34:21 +1200" MODIFIED_BY="[Empty name]">
<P>Prospective observational study </P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-06-06 09:34:24 +1200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Beckers-1999">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-06-06 09:34:24 +1200" MODIFIED_BY="[Empty name]">
<P>Prospective observational study </P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-06-02 08:52:23 +1200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Benkhalifa-2009">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-06-02 08:52:23 +1200" MODIFIED_BY="[Empty name]">
<P>Observational study</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-06-06 09:34:30 +1200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Bos_x002d_Mikich-2011">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-06-06 09:34:30 +1200" MODIFIED_BY="[Empty name]">
<P>Observational study </P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-06-06 09:34:33 +1200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Buckett-2005">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-06-06 09:34:33 +1200" MODIFIED_BY="[Empty name]">
<P>Retrospective observational study </P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-05-29 10:12:16 +1200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Buckett-2007">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-05-29 10:12:16 +1200" MODIFIED_BY="[Empty name]">
<P>Retrospective analysis</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2011-03-11 13:28:00 +1300" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Buckett-2008">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2011-03-11 13:28:00 +1300" MODIFIED_BY="[Empty name]">
<P>Retrospective study</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2011-03-11 13:28:00 +1300" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Cha-1998">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2011-03-11 13:28:00 +1300" MODIFIED_BY="[Empty name]">
<P>Retrospective case-control study</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-06-06 09:34:39 +1200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Cha-2000">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-06-06 09:34:39 +1200" MODIFIED_BY="[Empty name]">
<P>Prospective observational study </P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-06-06 09:34:43 +1200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Cha-2005">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-06-06 09:34:43 +1200" MODIFIED_BY="[Empty name]">
<P>Prospective observational study </P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-06-06 09:34:50 +1200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Chian-1999">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-06-06 09:34:50 +1200" MODIFIED_BY="[Empty name]">
<P>Retrospective observational study (as letter to the editor) </P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-06-06 09:34:55 +1200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Chian-2000">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-06-06 09:34:55 +1200" MODIFIED_BY="[Empty name]">
<P>Prospective randomised study </P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2011-03-11 13:28:09 +1300" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Chian-2004">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2011-03-11 13:28:09 +1300" MODIFIED_BY="[Empty name]">
<P>Case series</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-06-06 09:35:00 +1200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Child-2001">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-06-06 09:35:00 +1200" MODIFIED_BY="[Empty name]">
<P>Retrospective case-control study </P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-06-06 09:35:04 +1200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Child-2002">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-06-06 09:35:04 +1200" MODIFIED_BY="[Empty name]">
<P>Prospective observational study </P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-06-06 09:34:08 +1200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Choi-2012">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-06-06 09:34:08 +1200" MODIFIED_BY="[Empty name]">
<P>Non RCT</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-07-18 13:11:17 +1200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Chung-2000">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-07-18 13:11:17 +1200" MODIFIED_BY="[Empty name]">
<P>Prospective randomised study comparing HCG priming and not in women with PCOS undergoing IVM</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-06-06 09:35:27 +1200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Filali-2008">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-06-06 09:35:27 +1200" MODIFIED_BY="[Empty name]">
<P>Retrospective observational study</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-06-06 09:35:33 +1200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Fukuda-2006">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-06-06 09:35:33 +1200" MODIFIED_BY="[Empty name]">
<P>Retrospective observational study </P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-07-18 13:11:26 +1200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Ge-2008">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-07-18 13:11:26 +1200" MODIFIED_BY="[Empty name]">
<P>Prospective randomised study comparing different culture media in 62 women with PCOS undergoing IVM</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-05-29 10:10:34 +1200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Gremeau-2012">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-05-29 10:10:34 +1200" MODIFIED_BY="[Empty name]">
<P>Retrospective case&#8211;control study</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2011-03-11 13:28:15 +1300" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Gulekli-2004">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2011-03-11 13:28:15 +1300" MODIFIED_BY="[Empty name]">
<P>Prospective controlled study of priming with 10,000 versus 20,000 IU of HCG in 57 women with PCOS undergoing IVM</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-06-06 09:35:45 +1200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Harris-2010">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-06-06 09:35:45 +1200" MODIFIED_BY="[Empty name]">
<P>Prospective observational study </P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-06-06 09:35:49 +1200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Holzer-2006">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-06-06 09:35:49 +1200" MODIFIED_BY="[Empty name]">
<P>Prospective observational study </P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-06-06 09:35:57 +1200" MODIFIED_BY="jane clarke" STUDY_ID="STD-Hreinsson-2003">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-06-06 09:35:57 +1200" MODIFIED_BY="jane clarke">
<P>Randomised prospective study comparing LH and HCG for oocyte maturation in an IVM program</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-05-29 10:10:12 +1200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Junk-2012">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-05-29 10:10:12 +1200" MODIFIED_BY="[Empty name]">
<P>Prospective cohort study</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-08-19 16:55:07 +1200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Kim-2013">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-08-19 16:55:07 +1200" MODIFIED_BY="[Empty name]">
<P>RCT evaluating the effect of melatonin supplementation on the clinical outcomes of IVM IVF transfer in 111 women with PCOS</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-06-06 09:36:10 +1200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Le-Du-2005">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-06-06 09:36:10 +1200" MODIFIED_BY="[Empty name]">
<P>Retrospective observational study </P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-06-06 09:36:14 +1200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Li-2005">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-06-06 09:36:14 +1200" MODIFIED_BY="[Empty name]">
<P>Prospective observational study </P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-06-06 09:36:17 +1200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Lim-2009">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-06-06 09:36:17 +1200" MODIFIED_BY="[Empty name]">
<P>Retrospective analysis </P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-06-06 09:36:20 +1200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Lin-2003">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-06-06 09:36:20 +1200" MODIFIED_BY="[Empty name]">
<P>Prospective observational study </P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-06-06 09:36:24 +1200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Liu-2010">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-06-06 09:36:24 +1200" MODIFIED_BY="[Empty name]">
<P>Prospective observational study </P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-06-02 23:03:30 +1200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Lornage-2006">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-06-02 23:03:30 +1200" MODIFIED_BY="[Empty name]">
<P>Retrospective analysis</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-07-18 13:11:36 +1200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Mikkelsen-2001">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-07-18 13:11:36 +1200" MODIFIED_BY="[Empty name]">
<P>Randomised prospective study of 36 women with PCOS comparing priming and no priming with FSH before IVM.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-07-18 13:11:46 +1200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Mikkelsen-2003">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-07-18 13:11:46 +1200" MODIFIED_BY="[Empty name]">
<P>Randomised prospective study on the interval between FSH administration and IVM in women with PCOS</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-06-02 08:34:49 +1200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Roesner-2012">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-06-02 08:34:49 +1200" MODIFIED_BY="[Empty name]">
<P>Retrospective analysis</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-06-06 09:36:57 +1200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Sandraa-2006">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-06-06 09:36:57 +1200" MODIFIED_BY="[Empty name]">
<P>Retrospective observational study </P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-06-06 09:37:05 +1200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Shalom_x002d_Paz-2012">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-06-06 09:37:05 +1200" MODIFIED_BY="[Empty name]">
<P>Retrospective evaluation </P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-06-06 09:37:10 +1200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Shu_x002d_Shi-2006">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-06-06 09:37:10 +1200" MODIFIED_BY="[Empty name]">
<P>Retrospective observational study</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-06-06 09:37:15 +1200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Soderstrom_x002d_Anttila-2005">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-06-06 09:37:15 +1200" MODIFIED_BY="[Empty name]">
<P>Retrospective observational study </P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-06-06 09:37:20 +1200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Son-2005">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-06-06 09:37:20 +1200" MODIFIED_BY="[Empty name]">
<P>Retrospective observational study</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-05-29 10:07:33 +1200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Son-2007">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-05-29 10:07:33 +1200" MODIFIED_BY="[Empty name]">
<P>Non RCT</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-06-06 09:37:26 +1200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Trounson-1994">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-06-06 09:37:26 +1200" MODIFIED_BY="[Empty name]">
<P>Retrospective observational study </P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-07-18 14:11:23 +1200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Vieira-2008">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-07-18 14:11:23 +1200" MODIFIED_BY="[Empty name]">
<P>Prospective controlled trial in 5 PCOS patients and 8 patients with male or tubal causes of subfertility undergoing IVM comparing the meiotic spindle and chromosomal distribution of IVM oocytes and IVM rates</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-07-18 14:11:29 +1200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Vieira-2010">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-07-18 14:11:29 +1200" MODIFIED_BY="[Empty name]">
<P>Prospective controlled trial in 13 PCOS patients and 27 patients with male or tubal causes of subfertility undergoing IVM comparing the meiotic spindle and chromosomal distribution of IVM oocytes and IVM rates</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-08-19 16:37:37 +1200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Walls-2012">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-08-19 16:37:37 +1200" MODIFIED_BY="[Empty name]">
<P>RCT comparing ICSI with IVF in 8 women with PCOS</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-05-29 10:05:48 +1200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Xu-2012">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-05-29 10:05:48 +1200" MODIFIED_BY="[Empty name]">
<P>Non RCT</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-05-29 09:37:20 +1200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Yu-2012">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-05-29 09:37:20 +1200" MODIFIED_BY="[Empty name]">
<P>Retrospective study</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-06-06 09:37:38 +1200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Zhang-2007">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-06-06 09:37:38 +1200" MODIFIED_BY="[Empty name]">
<P>Observational study </P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-06-06 09:37:44 +1200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Zhao-2006">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-06-06 09:37:44 +1200" MODIFIED_BY="[Empty name]">
<P>Retrospective observational study</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2011-03-11 13:28:35 +1300" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Zhao-2009">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2011-03-11 13:28:35 +1300" MODIFIED_BY="[Empty name]">
<P>Retrospective study</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-08-19 16:45:14 +1200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Zheng-2012">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-08-19 16:45:14 +1200" MODIFIED_BY="[Empty name]">
<P>RCT of 82 women with PCOS undergoing IVM cycles, randomly assigned to be hCG primed or not primed</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<FOOTNOTES>
<P>FSH: follicle stimulating hormone<BR/>HCG: human chorionic gonadotrophin<BR/>IU: international units<BR/>IVM: in vitro maturation<BR/>LH: luteinising hormone<BR/>PCOS: polycystic ovarian syndrome<BR/>RCT: randomised controlled trial<BR/>
</P>
</FOOTNOTES>
</CHARACTERISTICS_OF_EXCLUDED_STUDIES>
<CHARACTERISTICS_OF_AWAITING_STUDIES MODIFIED="2013-05-27 04:29:18 +1200" MODIFIED_BY="[Empty name]" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<FOOTNOTES/>
</CHARACTERISTICS_OF_AWAITING_STUDIES>
<CHARACTERISTICS_OF_ONGOING_STUDIES MODIFIED="2013-08-06 03:05:48 +1200" MODIFIED_BY="[Empty name]" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<ONGOING_CHAR MODIFIED="2013-08-06 03:05:48 +1200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Bruin-2010">
<CHAR_STUDY_NAME MODIFIED="2013-06-05 06:39:41 +1200" MODIFIED_BY="[Empty name]">
<P>A multicentre randomised controlled trial comparing in vitro maturation of oocytes with in vitro fertilisation in women with an increased risk of ovarian hyperstimulation syndrome</P>
</CHAR_STUDY_NAME>
<CHAR_METHODS MODIFIED="2013-06-05 06:40:16 +1200" MODIFIED_BY="[Empty name]">
<P>Multicentre randomised active controlled parallel group trial with non-randomised pilot study</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-08-06 03:05:48 +1200" MODIFIED_BY="[Empty name]">
<P>Target sample size 450 (400 couples, preceded by a pilot study of 50 non-randomised IVM cycles)</P>
<P>Inclusion criteria:</P>
<P>1. Women with Polycystic Ovarian Syndrome (PCOS) according to the Rotterdam Criteria (The Rotterdam European Society of Human Reproduction and Embryology [ESHRE] /American Society for Reproductive Medicine [ASRM] - Sponsored PCOS consensus workshop group, 2004) who not did achieve an ongoing pregnancy after ovulation induction (with clomiphene citrate or Laparoscopic Electrocoagulation of the Ovaries (LEO) and Recombinant Follicle Stimulating Hormone [rFSH])<BR/>2. Women with an IVF or ICSI indication and increased risk for developing Ovarian Hyperstimulation Syndrome (OHSS) (history of OHSS or cycle cancellation for imminent OHSS</P>
<P>Exclusion criteria:</P>
<P>1. Woman or partner younger than 18 years and woman older than 38 years<BR/>2. Unable to speak or read the Dutch language<BR/>3. Medical contraindication for pregnancy or childbirth<BR/>4. Positive serology for Hepatitis B, C or HIV<BR/>5. Diminished ovarian reserve: early follicular serum FSH &gt; 10 IU/L and/or poor response during earlier COH/IVF or COH/ICSI with &#8805; 150 IU rFSH/day<BR/>6. Persisting ovarian cysts &gt; 30 mm diameter</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-08-05 20:51:07 +1200" MODIFIED_BY="[Empty name]">
<P>Patients will be randomised to:<BR/>
<BR/>1. IVM/ICSI strategy<BR/>1.1. The maximum number of IVM cycles per patient is two.<BR/>1.2. The IVM cycle will be sonographically and endocrinologically monitored (serum estradiol concentration).<BR/>1.3. In patients with severe oligomenorrhoea or amenorrhoea priming of the ovaries can be performed (after induction of withdrawal bleeding with 7 days 10mg progestogens orally, if necessary).<BR/>1.4. Ovarian priming consists of subcutaneous administration of 150 IE rFSH on cycle days 3 through 5.<BR/>1.5. In primed cycles 10,000 IE of hCG will be administered subcutaneously when the dominant follicle is identified. Oocyte retrieval is scheduled 38 hours after administration of hCG.<BR/>1.6. Directly after oocyte retrieval luteal support is started by estradiol 2 mg orally three times a day and progesterone 200 mg vaginally three times a day from oocyte retrieval plus one day.<BR/>1.7. A maximum number of two embryos will be transferred per cycle. Remaining embryos can be selected for cryopreservation according to the standard IVF/ICSI procedures and criteria.<BR/>
<BR/>2. IVF/ICSI strategy<BR/>2.1. The maximum number of IVF/ICSI cycles per patient is one.<BR/>2.2. After pre-treatment with an oral contraceptive pill or induction of withdrawal bleeding with 7 days 10 mg progestogens orally, COH will be started from the 4th day after the end of pre-treatment with daily subcutaneous injections with 100-225 EH rFSH. From stimulation day 6 onwards a GnRH antagonist (0.25 mg) will be daily injected subcutaneously for pituitary down regulation.<BR/>2.3. The cycle will be sonographically monitored starting at day 3 after stopping oral contraception (baseline ultrasound). When acquired numbers and diameters of follicles are reached 10,000 IE of hCG is administered subcutaneously and oocyte retrieval scheduled for 34-36 hours after hCG. After oocyte retrieval standard IVF or ICSI procedure will follow.<BR/>2.4. Directly after oocyte retrieval luteal support is started by administration of progesterone 200 mg vaginally two times a day.<BR/>2.5. The maximum number of embryos that can be transferred is two. Remaining embryos can be selected for cryopreservation according to standard IVF/ICSI procedures and criteria.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-08-05 20:51:37 +1200" MODIFIED_BY="[Empty name]">
<P>Primary outcome:</P>
<P>Cumulative live birth rate after IVM/ICSI or COH/IVF/ICSI strategy including pregnancies from cryoembryos transferred within 12 months after the end of IVM/ICSI or COH/IVF/ICSI treatment.<BR/>Secondary outcome:</P>
<P>1. Pregnancy/Childbirth:<BR/>Detailed information on maternal complications will be obtained from the obstetrician treating the woman concerned. Six weeks after the expected day of delivery all women will be contacted by telephone to ask information on the delivery and on the health of the child, and for consent to contact the health centre where she gave birth. If a child has been hospitalised the paediatrician treating the child will be contacted for further information.<BR/>2. Paediatric follow-up:<BR/>Follow-up will consist of evaluation on the following domains using internationally accredited and validated tests: motor development, cognitive development, and behaviour.<BR/>Follow-up visits will be scheduled at ages of 6 months, 1, 2, and 5 years.<BR/>3. Economic evaluation:<BR/>A distinction will be made between costs of medical interventions (direct costs) and costs resulting from productivity losses (indirect or time costs). Standardised unit costs will be calculated for all centres based on actual expenses made during the study. Subsequently, unit costs will be applied to resource use as observed in the participating centres.<BR/>Resource utilisation will be documented using individual patient data in the case record forms. In addition, each woman will receive a questionnaire for details on associated direct costs of professional care, and on indirect costs like transportation and productivity loss. These questionnaires will be sent 4 weeks, 12 weeks, 24 weeks and 48 weeks after treatment start.<BR/>Resource unit prices will reflect the unit of staff, materials, equipment, housing, depreciation, and overhead. End point for cost-effectiveness will be Euros/live-birth for either strategy.<BR/>4. Patient quality of life study:<BR/>Before starting a treatment cycle, the day before oocyte retrieval and the day after oocyte retrieval and 3 weeks after a treatment cycle patients will be asked to fill out a validated questionnaire on quality of life (Fertiqol questionnaire, www.fertiqol.org).</P>
</CHAR_OUTCOMES>
<CHAR_STARTING_DATE MODIFIED="2013-06-05 06:25:43 +1200" MODIFIED_BY="[Empty name]">
<P>1/1/2010</P>
</CHAR_STARTING_DATE>
<CHAR_CONTACT_INFORMATION MODIFIED="2013-08-05 20:39:05 +1200" MODIFIED_BY="[Empty name]">
<P>Register: Netherlands Trial Register</P>
<P>Primary sponsor: Jeroen Bosch Hospital</P>
<P>Name: J.P. Bruin, de<BR/>Address: Postbus 90153 5200 Center for Reproductive Medicine P.O. Box 90153 ME Den Bosch The Netherlands<BR/>Telephone: +31 (0)73 6998660<BR/>Email:j.d.bruin@jbz.nl</P>
</CHAR_CONTACT_INFORMATION>
<CHAR_NOTES MODIFIED="2013-08-05 20:38:59 +1200" MODIFIED_BY="[Empty name]">
<P>Trial website: http://www.studies-obsgyn.nl/ivm</P>
<P>Status of trial: Completed</P>
</CHAR_NOTES>
</ONGOING_CHAR>
<ONGOING_CHAR MODIFIED="2013-08-05 20:42:36 +1200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Massey-2010">
<CHAR_STUDY_NAME MODIFIED="2013-08-05 20:42:36 +1200" MODIFIED_BY="[Empty name]">
<P>In vitro maturation with in vitro fertilisation (IVF) compared to mild in vitro fertilisation (IVM vs IVF)<BR/>
</P>
</CHAR_STUDY_NAME>
<CHAR_METHODS MODIFIED="2013-08-05 20:41:06 +1200" MODIFIED_BY="[Empty name]">
<P>Allocation: Randomised<BR/>Endpoint Classification: Efficacy study<BR/>Intervention Model: Cross-over assignment<BR/>Masking: Open label<BR/>Primary Purpose: Health Services Research</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-08-05 20:41:58 +1200" MODIFIED_BY="[Empty name]">
<P>Ages: 21 to 41 Years</P>
<P>Inclusion Criteria: Under age 42 female, normal uterine cavity, BMI 18-34 kg/m2<BR/>Exclusion Criteria: Donor eggs, donor sperm, myoma over 5 cm, current hydrosalpinx, abnormal uterine cavity</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-05-30 07:55:45 +1200" MODIFIED_BY="[Empty name]">
<P>Arm 1: IVM and IVF. No stimulation with gonadotropins, eggs harvested early</P>
<P>Arm 2: mild IVF (Low doses of gonadotropin stimulation followed by conventional IVF)<BR/>
</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-05-30 07:56:34 +1200" MODIFIED_BY="[Empty name]">
<P>Primary Outcome Measures: cost effectiveness <BR/>Secondary Outcome Measures: ongoing pregnancy rates per cycle</P>
</CHAR_OUTCOMES>
<CHAR_STARTING_DATE MODIFIED="2013-05-30 07:56:48 +1200" MODIFIED_BY="[Empty name]">
<P>March 2009</P>
</CHAR_STARTING_DATE>
<CHAR_CONTACT_INFORMATION MODIFIED="2013-05-30 07:57:46 +1200" MODIFIED_BY="[Empty name]">
<P>Joe B Massey, MD, Batzofin Fertility Services</P>
</CHAR_CONTACT_INFORMATION>
<CHAR_NOTES MODIFIED="2013-05-30 09:14:01 +1200" MODIFIED_BY="[Empty name]">
<P>This study has suspended participant recruitment (investigator changed location, requires new training effort)</P>
<P>ClinicalTrials.gov identifier: NCT00867763</P>
</CHAR_NOTES>
</ONGOING_CHAR>
<ONGOING_CHAR MODIFIED="2013-08-06 02:36:29 +1200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Shavit-2012">
<CHAR_STUDY_NAME MODIFIED="2013-08-05 20:43:17 +1200" MODIFIED_BY="[Empty name]">
<P>Comparison between two fertility protocols in obese polycystic ovary syndrome patients</P>
</CHAR_STUDY_NAME>
<CHAR_METHODS MODIFIED="2013-08-05 20:43:37 +1200" MODIFIED_BY="[Empty name]">
<P>Allocation: Randomised<BR/>Endpoint Classification: Efficacy study<BR/>Intervention Model: Parallel assignment<BR/>Masking: Open label<BR/>Primary Purpose: Treatment</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-08-05 20:49:58 +1200" MODIFIED_BY="[Empty name]">
<P>Estimated enrolment:40 patients</P>
<P>Age: 18 Years to 40 Years</P>
<P>Inclusion Criteria: BMI &gt; 30, PCOS, failure of COH treatment</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-08-06 02:36:29 +1200" MODIFIED_BY="[Empty name]">
<P>Arm 1: IVM treatment<BR/>No gonadotropin stimulation. Ovum pick-up will be from antral follicles of immature oocyte which will be matured in the lab and fertilised by ICSI. Embryo transfer will take place on days 2 or 3.</P>
<P>Arm 2: IVF antagonist protocol<BR/>Stimulation with gonadotropins and use of GnRH antagonists. Ovulation induction will be performed with GnRH agonist. After ovulation there will be ovum pick-up and fertilisation in the lab. Embryo transfer will take place on days 2 or 3.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-05-30 07:59:15 +1200" MODIFIED_BY="[Empty name]">
<P>Reported as "fertility results"</P>
</CHAR_OUTCOMES>
<CHAR_STARTING_DATE MODIFIED="2013-05-30 07:14:18 +1200" MODIFIED_BY="[Empty name]">
<P>April 2012</P>
</CHAR_STARTING_DATE>
<CHAR_CONTACT_INFORMATION MODIFIED="2013-05-30 07:14:12 +1200" MODIFIED_BY="[Empty name]">
<P>Tal Shavit, MD972-50-6246712, e-mail: tal.shavit@gmail.com</P>
</CHAR_CONTACT_INFORMATION>
<CHAR_NOTES MODIFIED="2013-05-30 08:01:13 +1200" MODIFIED_BY="[Empty name]">
<P>This study is not yet open for participant recruitment</P>
<P>Hillel Yaffe Medical Center, Hadera, Israel, 38100</P>
<P>ClinicalTrials.gov identifier: NCT01473459</P>
</CHAR_NOTES>
</ONGOING_CHAR>
<FOOTNOTES>
<P>BMI: body mass index<BR/>COH: controlled ovarian hyperstimulation<BR/>GnRH: gonadotrophin-releasing hormone<BR/>HCG: human chorionic gonadotrophin<BR/>ICSI: intracytoplasmic sperm injection<BR/>IU: international units<BR/>IVF: in vitro fertilisation<BR/>IVM: in vitro maturation<BR/>PCOS: polycystic ovarian syndrome<BR/>
</P>
</FOOTNOTES>
</CHARACTERISTICS_OF_ONGOING_STUDIES>
</CHARACTERISTICS_OF_STUDIES>
<QUALITY_ITEMS MODIFIED="2013-06-06 09:33:33 +1200" MODIFIED_BY="[Empty name]">
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-01" LEVEL="STUDY" MODIFIED="2013-06-06 09:33:33 +1200" MODIFIED_BY="[Empty name]" NO="1">
<NAME>Random sequence generation (selection bias)</NAME>
<DESCRIPTION>
<P>Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-02" LEVEL="STUDY" MODIFIED="2013-06-06 09:33:33 +1200" MODIFIED_BY="[Empty name]" NO="2">
<NAME>Allocation concealment (selection bias)</NAME>
<DESCRIPTION>
<P>Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-03" LEVEL="GROUP" NO="3">
<NAME>Blinding (performance bias and detection bias)</NAME>
<DESCRIPTION>
<P>Performance bias or detection bias due to knowledge of the allocated interventions after assignment</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-04" LEVEL="GROUP" MODIFIED="2013-06-06 09:33:33 +1200" MODIFIED_BY="[Empty name]" NO="4">
<NAME>Incomplete outcome data (attrition bias)</NAME>
<DESCRIPTION>
<P>Attrition bias due to amount, nature or handling of incomplete outcome data</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-04.01" NO="1">
<NAME>All outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-05" LEVEL="STUDY" MODIFIED="2013-06-06 09:33:33 +1200" MODIFIED_BY="[Empty name]" NO="5">
<NAME>Selective reporting (reporting bias)</NAME>
<DESCRIPTION>
<P>Reporting bias due to selective outcome reporting</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-06" LEVEL="STUDY" MODIFIED="2013-06-06 09:33:33 +1200" MODIFIED_BY="[Empty name]" NO="6">
<NAME>Other bias</NAME>
<DESCRIPTION>
<P>Bias due to problems not covered elsewhere in the table</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-07" LEVEL="GROUP" MODIFIED="2013-06-06 09:33:33 +1200" MODIFIED_BY="[Empty name]" NO="7">
<NAME>Blinding of participants and personnel (performance bias)</NAME>
<DESCRIPTION>
<P>Performance bias due to knowledge of the allocated interventions by participants and personnel during the study</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-07.01" NO="1">
<NAME>All outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-08" LEVEL="GROUP" MODIFIED="2013-06-06 09:33:33 +1200" MODIFIED_BY="[Empty name]" NO="8">
<NAME>Blinding of outcome assessment (detection bias)</NAME>
<DESCRIPTION>
<P>Detection bias due to knowledge of the allocated interventions by outcome assessors</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-08.01" NO="1">
<NAME>All outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
</QUALITY_ITEMS>
<SOF_TABLES/>
<ADDITIONAL_TABLES/>
<ANALYSES_AND_DATA CALCULATED_DATA="YES"/>
<FIGURES/>
<FEEDBACK/>
<APPENDICES MODIFIED="2013-06-06 02:59:12 +1200" MODIFIED_BY="jane clarke">
<APPENDIX ID="APP-01" MODIFIED="2008-10-29 09:41:15 +1300" MODIFIED_BY="jane clarke" NO="1">
<TITLE MODIFIED="2008-05-05 12:28:49 +1200" MODIFIED_BY="jane clarke">MEDLINE search strategy</TITLE>
<APPENDIX_BODY MODIFIED="2008-10-29 09:41:15 +1300" MODIFIED_BY="jane clarke">
<P>1 Polycystic Ovary Syndrome/ (6318)</P>
<P>2 (polycystic adj5 ovar$).ti,ab,sh. (5620)</P>
<P>3 PCOS.ti,ab,sh. (2443)</P>
<P>4 PCOD.ti,ab,sh. (242)</P>
<P>5 (stein-leventhal or leventhal).tw. (613)</P>
<P>6 (ovar$ adj (sclerocystic or polycystic or degeneration)).tw. (47)</P>
<P>7 or/1-6 (7611)</P>
<P>8 (in vitro adj5 matur$).tw. (5204)</P>
<P>9 IVM.tw. (810)</P>
<P>10 (oocyte$ adj5 matur$).tw. (7283)</P>
<P>11 (immatur$ adj5 oocyte$).tw. (1229)</P>
<P>12 or/8-11 (10755)</P>
<P>13 7 and 12 (133)</P>
<P>14 randomised controlled trial.pt. (234274)</P>
<P>15 controlled clinical trial.pt. (74820)</P>
<P>16 Randomized Controlled Trials/ (48327)</P>
<P>17 Random allocation/ (57750)</P>
<P>18 Double-blind method/ (91028)</P>
<P>19 Single-blind method/ (10880)</P>
<P>20 or/14-19 (397294)</P>
<P>21 clinical trial.pt. (435392)</P>
<P>22 exp clinical trials/ (190560)</P>
<P>23 (clin$ adj25 trial$).ti,ab,sh. (129372)</P>
<P>24 ((singl$ or doubl$ or tripl$ or trebl$) adj25 (blind$ or mask$)).ti,ab,sh. (90362)</P>
<P>25 Placebos/ (26128)</P>
<P>26 placebo$.ti,ab,sh. (114490)</P>
<P>27 random$.ti,ab,sh. (490003)</P>
<P>28 Research design/ (47276)</P>
<P>29 or/21-28 (866440)</P>
<P>30 animal/ not (human/ and animal/) (3095759)</P>
<P>31 20 or 29 (873731)</P>
<P>32 31 not 30 (800552)</P>
<P>33 13 and 32 (26)</P>
<P>34 from 33 keep 1-26 (26)</P>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-02" MODIFIED="2008-09-04 06:20:31 +1200" MODIFIED_BY="[Empty name]" NO="2">
<TITLE MODIFIED="2008-05-12 13:12:44 +1200" MODIFIED_BY="jane clarke">CENTRAL search</TITLE>
<APPENDIX_BODY MODIFIED="2008-09-04 06:20:31 +1200" MODIFIED_BY="[Empty name]">
<P>1 Polycystic Ovary Syndrome/ (386)</P>
<P>2 (polycystic adj5 ovar$).ti,ab,sh. (553)</P>
<P>3 PCOS.ti,ab,sh. (343)</P>
<P>4 PCOD.ti,ab,sh. (26)</P>
<P>5 (stein-leventhal or leventhal).tw. (4)</P>
<P>6 (ovar$ adj (sclerocystic or polycystic or degeneration)).tw. (1)</P>
<P>7 or/1-6 (612)</P>
<P>8 (in vitro adj5 matur$).tw. (94)</P>
<P>9 IVM.tw. (22)</P>
<P>10 (oocyte$ adj5 matur$).tw. (220)</P>
<P>11 (immatur$ adj5 oocyte$).tw. (42)</P>
<P>12 or/8-11 (261)</P>
<P>13 7 and 12 (24)</P>
<P>14 from 13 keep 1-24 (24)</P>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-03" MODIFIED="2013-06-02 09:38:49 +1200" MODIFIED_BY="[Empty name]" NO="3">
<TITLE MODIFIED="2013-06-02 09:38:49 +1200" MODIFIED_BY="jane clarke">CINAHL search</TITLE>
<APPENDIX_BODY MODIFIED="2008-09-04 06:20:37 +1200" MODIFIED_BY="[Empty name]">
<P>1 Polycystic Ovary Syndrome/ (344)</P>
<P>2 (polycystic adj5 ovar$).ti,ab,sh. (261)</P>
<P>3 PCOS.ti,ab,sh. (118)</P>
<P>4 PCOD.ti,ab,sh. (5)</P>
<P>5 (stein-leventhal or leventhal).tw. (37)</P>
<P>6 (ovar$ adj (sclerocystic or polycystic or degeneration)).tw. (0)</P>
<P>7 or/1-6 (440)</P>
<P>8 (in vitro adj5 matur$).tw. (8)</P>
<P>9 IVM.tw. (3)</P>
<P>10 (oocyte$ adj5 matur$).tw. (16)</P>
<P>11 (immatur$ adj5 oocyte$).tw. (1)</P>
<P>12 or/8-11 (24)</P>
<P>13 7 and 12 (2)</P>
<P>14 from 13 keep 1-2 (2)</P>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-04" MODIFIED="2008-10-29 09:41:23 +1300" MODIFIED_BY="jane clarke" NO="4">
<TITLE MODIFIED="2008-05-12 13:14:50 +1200" MODIFIED_BY="jane clarke">EMBASE search</TITLE>
<APPENDIX_BODY MODIFIED="2008-10-29 09:41:23 +1300" MODIFIED_BY="jane clarke">
<P>1 Polycystic Ovary Syndrome/ (6476)</P>
<P>2 (polycystic adj5 ovar$).ti,ab,sh. (5365)</P>
<P>3 PCOS.ti,ab,sh. (2576)</P>
<P>4 PCOD.ti,ab,sh. (235)</P>
<P>5 (stein-leventhal or leventhal).tw. (131)</P>
<P>6 (ovar$ adj (sclerocystic or polycystic or degeneration)).tw. (28)</P>
<P>7 or/1-6 (7230)</P>
<P>8 (in vitro adj5 matur$).tw. (3913)</P>
<P>9 IVM.tw. (536)</P>
<P>10 (oocyte$ adj5 matur$).tw. (5512)</P>
<P>11 (immatur$ adj5 oocyte$).tw. (988)</P>
<P>12 or/8-11 (8338)</P>
<P>13 7 and 12 (149)</P>
<P>14 Controlled study/ or randomised controlled trial/ (2405316)</P>
<P>15 double blind procedure/ (63789)</P>
<P>16 single blind procedure/ (6559)</P>
<P>17 crossover procedure/ (18585)</P>
<P>18 drug comparison/ (81250)</P>
<P>19 placebo/ (97915)</P>
<P>20 random$.ti,ab,hw,tn,mf. (367123)</P>
<P>21 latin square.ti,ab,hw,tn,mf. (1064)</P>
<P>22 crossover.ti,ab,hw,tn,mf. (32554)</P>
<P>23 cross-over.ti,ab,hw,tn,mf. (11275)</P>
<P>24 placebo$.ti,ab,hw,tn,mf. (146355)</P>
<P>25 ((doubl$ or singl$ or tripl$ or trebl$) adj5 (blind$ or mask$)).ti,ab,hw,tn,mf. (106285)</P>
<P>26 (comparative adj5 trial$).ti,ab,hw,tn,mf. (5769)</P>
<P>27 (clinical adj5 trial$).ti,ab,hw,tn,mf. (483066)</P>
<P>28 or/14-27 (2886258)</P>
<P>29 nonhuman/ (2878264)</P>
<P>30 animal/ not (human/ and animal/) (12847)</P>
<P>31 or/29-30 (2881866)</P>
<P>32 28 not 31 (1695407)</P>
<P>33 13 and 32 (67)</P>
<P>34 from 33 keep 1-67 (67)</P>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-05" MODIFIED="2013-06-06 02:59:12 +1200" MODIFIED_BY="[Empty name]" NO="5">
<TITLE MODIFIED="2013-06-06 02:59:12 +1200" MODIFIED_BY="[Empty name]">Clinicaltrials.gov and WHO portal for ongoing trials search</TITLE>
<APPENDIX_BODY MODIFIED="2013-06-05 06:34:27 +1200" MODIFIED_BY="[Empty name]">
<P>1 Polycystic Ovary Syndrome</P>
<P>2 PCOS</P>
<P>3 stein-leventhal or leventhal</P>
<P>4 In vitro adj matur$</P>
<P>5 IVM</P>
<P>6 In vitro maturation</P>
</APPENDIX_BODY>
</APPENDIX>
</APPENDICES>
<EXTENSIONS/>
</COCHRANE_REVIEW>